




INHIBITION OF THE OXIDOREDUCTASE ENZYME DPRE1 OF 














A thesis submitted to the 
University of Birmingham 
for the degree of 





Institute of Microbiology and Infection 
School of Biosciences 
College of Life Sciences 
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 






Inhibition of the oxidoreductase enzyme DprE1 of Mycobacterium tuberculosis by 
two small compounds 
DprE1 is an essential oxidoreductase enzyme found in the pathogen Mycobacterium 
tuberculosis, the causative agent of the disease tuberculosis. The recent emergence of 
multi-drug (MDR-) and extensively-drug resistant (XDR-TB) strains of TB has 
highlighted the need for new drugs to complement an outdated treatment regimen. 
This project details the purification of DprE1 and the efforts made to characterize its 
interaction with two small compounds thought to be inhibitors, 1326 and 1328. The 
Kd value of each compound was determined and the design of two plasmids for the 
overexpression of Pseudomonas aeruginosa and Mycobacterium smegmatis DprE1 
homologues was detailed.  
 
Investigating the role of the chaperonins of Mycobacterium marinum 
The chaperonins are a distinct subset of molecular chaperones. Homologues of the 
essential E. coli chaperonin GroEL have been identified across the Mycobacteria 
family of bacteria. Gene knockout of Cpn60.1 (cpn60.1) has been achieved in 
Mycobacterium marinum, a fish pathogen closely related to the human pathogen M. 
tuberculosis. In this project efforts have been made to characterize this cpn60.1-
knockout strain of M. marinum; determining growth curves, lipid profiles, response to 
heat-shock, ability to form biofilms and relative levels of expression of each cpn gene 
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In 2010, Mycobacterium tuberculosis, the causative agent of the disease tuberculosis 
(TB) was responsible for 8.8 million cases of TB of which 1.1 million were fatal. The 
courses of treatment for TB has remained relatively unchanged for the past 50 years 
allowing the development of multidrug-resistant TB (MDR-TB) and extensively drug-
resistant TB (XDR-TB). Research has led to the identification of new inhibitors and 
potential drug targets against TB. One such target is the oxidoreductase enzyme 
DprE1, an essential enzyme in Mycobacteria that is required for the synthesis of cell 
wall arabinan. The dinitrobenzamides, benzothiazonines and azaindoles, are three 
classes of compounds that have all been identified as inhibitors of DprE1. As part of 
the ongoing drug-development process this paper outlines the efforts to characterise 
the binding of two known DprE1 inhibitors, 1328 and 1326. Using fluorescence 
spectroscopy, ligand-binding assays were performed to establish the dissociation 
constant (Kd) for each compound. Previous efforts to co-crystallise these inhibitors 
with DprE1 have been unsuccessful. In an attempt to overcome this, I detail the 
construction of two plasmids for the overexpression of the DprE1 homologues from 
Mycobacterium smegmatis and Pseudomonas aeruginosa. Efforts to purify M. 
smegmatis DprE1 have proven successful, whilst the P. aeruginosa enzyme is found 
to be mostly insoluble. Due to time constraints no ligand-binding studies were 
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1. INTRODUCTION 
1.1 Tuberculosis  
 
First described in 1882 by the German scientist Robert Koch (Fattorini, 2013) tuberculosis 
(TB) is a disease that has affected mankind for thousands of years (Hershkovitz et al., 2008). 
The disease is caused by certain members of the mycobacterium genus, most notably 
Mycobacterium tuberculosis and its related species; Mycobacterium africanum, 
Mycobacterium bovis, Mycobacterium microti, Mycobacterium caprae, Mycobacterium 
pinnipedii and Mycobacterium canettii (Zumla, Nahid and Cole, 2013). It is currently believed 
that many people are infected with latent tuberculosis. In 2010, 8.8 million incident cases of 
TB were reported with 1.1 million of these cases leading to fatalities (Mesfin et al, 2014). 
 
Fig. 1 Map showing prevalence of new TB cases across the world in 2010.  




1.2 M. tuberculosis mode of infection 
 
M. tuberculosis most commonly resides in the lungs, resulting in pulmonary TB but may also 
inhabit other areas of the body. Transmission of M. tuberculosis occurs via airborne droplets 
expectorated from infected individuals. The bacteria mostly reside in the phagosomal 
compartment of macrophage cells within the body (Ehrt & Rhee, 2013). By residing in these 
immune cells M. tuberculosis can effectively avoid the body’s immune defence and persist 
indefinitely unless treated with an intense regime of drugs. Certain groups are at greater risk 
of developing active TB, such as individuals with diabetes mellitus (Baghaei et al, 2013) and 
HIV-positive individuals (Mesfin et al, 2014). Patients with HIV are 20-fold more likely to 
develop active TB than non HIV-TB co-infected patients, with the disease being “the most 
common cause of AIDS-related death” (Pawlowski et al, 2012). Tuberculosis is most 
common among third-world populations where overcrowding, malnutrition and cases of HIV 
are prevalent (Fig. 1; Lawn & Zumla, 2011).  
 
M. tuberculosis exhibits a number of evolutionary adaptations that make it an excellent 
persister. Persistence refers to the ability of the bacteria to survive long-term within a host. M. 
tuberculosis has been shown to be able to persist for decades within the same host (Lillebaek 
et al., 2002). Once inhaled, M. tuberculosis cells travel to the small alveoli of the lungs where 
they are ingested by macrophages. Mobilisation of the host immune system in response to the 
pathogen creates an environment that would be inhospitable to most invading organisms. 
IFN-γ stimulates the macrophages to produce reactive oxygen species and increase acid stress 
(Saviola, 2013). The change in environmental conditions stimulates M. tuberculosis to elicit a 
stress response, altering the expression of key genes. 48 of these co-regulated key genes 
comprise the dormancy survival regulon (DosR), with their expression being controlled by the 
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response regulator DosR. This regulon is induced when the ability for aerobic respiration is 
inhibited, promoting the bacteria to enter a dormant, non-replicative state (Leistikow et al., 
2009). The regulon exists as a three-component system with DosR acting synergistically with 
the sensor histidine-kinases, DosT and DosS, which are activated in response to NO and CO 
(Leistikow et al., 2010; Sivaramakrishnan & Ortiz de Montellano, 2013). These dormant, or 
latent cells can remain viable for many years. The subsequent host adaptive immune response 
results in the migration of other immune cells, e.g. lymphocytes, to the site of infection. These 
cells eventually form a clump of cells, dubbed a granuloma, also known as the primary lesion 
or Ghon’s complex, which can become calcified (Delogu, Sali and Fadda, 2013). Reactivation 
of dormant TB cells requires stimuli by a family of molecules known as the resuscitation 
promoting factors (Rpf). The exact mode of re-emergence of dormant TB isn’t entirely known, 
however it is suggested that when a high density of replicative cells is reached the host 
immune response is stimulated. This could lead to the liquefaction of the primary granuloma, 
releasing the tubercule bacilli (Fattorini et al, 2013). 
 
1.3 Treatment of TB 
 
Due to the aforementioned adaptations of M. tuberculosis, treatment of infection is a drawn-
out multidrug process. The first drug discovered to show efficacy against TB was 
streptomycin, an aminogylcoside antibiotic derived from Streptomyces griseus. However, it 
was quickly discovered that single drug treatment of TB led to rapid development of 
antibiotic resistance (Zumla, Nahid & Cole, 2013). Current treatment of drug-susceptible 
pulmonary TB involves the use of four first-line drugs (FLDs); ethambutol, rifampicin, 
pyrazinamide and isoniazid. In areas affected by a high prevalence of antibiotic-resistant 
strains of TB, all four FLDs are administered in a Directly Observed Therapy, Short-Course 
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(DOTS) to ensure patient compliance with the drug regimen. This course of treatment takes at 
least six months – 2 months with daily doses of all 4 drugs, followed by a 4-month 
continuation phase consisting of isoniazid and rifampicin (Manca et al, 2013).  
 
Ethambutol (EMB) was first observed to alter cell morphology and reduce clumping in the 
M. tuberculosis-related organism Mycobacterium smegmatis. This observation was 
hypothesised to be a result of cell wall disruption (Kilburn and Greenberg, 1977). EMB has 
since been shown to inhibit cell wall biosynthesis, specifically the synthesis of two key 
components; arabinogalactan and lipoarabinomannan (LAM) (Goude et al, 2009). EMB 
targets the proteins coded for by the emb operon consisting of the genes embC, embA and 
embB.  This operon codes for three essential arabinosyltransferase enzymes EmbC, EmbA 
and EmbB. 
 
Rifampicin (RIF) inhibits RNA transcription in M. tuberculosis cells by binding with high-
affinity to the DNA-dependent RNA Polymerase (RNAP; Wehrli & Staehelin, 1971), more 
specifically to an area at the binding pocket within the DNA/RNA channel of the RNAP beta 
subunit (Campbell et al, 2001).  
 
Pyrazinamide (PZA) is given to patients in the form of a prodrug. It only becomes toxic to M. 
tuberculosis after the bacteria take up the compound. Once ingested it is converted to the 
active form, pyrazinoic acid (PZA) by the enzyme pyrazinamidase (PncA) enzyme 
(Rajendran et al., 2014), which inhibits protein and RNA synthesis as well as disrupting 
membrane potential at low pHs (Zhang et al, 2003). 
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Isoniazid or isonicotinylhydrazine (INH), like PZA is administered as a prodrug. It enters M. 
tuberculosis by passive diffusion, at which point it is converted to active forms by the 
Mycobacterium enzyme KatG. The KatG-catalysed peroxidation reaction of INH leads to the 
formation of two radicals: isonicotinic hydrazyl radical and isonicotinoyl radical (Timmins & 
Deretic, 2006). These radicals have been proposed to bind to NAD forming an INH-NAD 
adduct, which inhibits the enzyme inhA – an NADH-dependent enoyl-ACP reductase crucial 
for mycolic acid biosynthesis (Vilchèze & Jacobs, Jr., 2007).  
Although effective, these drugs can have side effects that increase morbidity from TB 
treatment, often leading to poor patient compliance (Yee et al., 2003). Ethambutol has been 
directly shown to cause ocular neuritis (swelling of the optic nerve; Griffith et al., 2005). A 
common side effect of Isoniazid is hepatotoxicity, which has been shown to affect around 
0.15% of patients, with risk of incidence increasing with age (Nolan, Goldberg & Buskin, 
1999). Rifampicin has been shown to affect the processing of other drugs administered in 
conjunction with it. This is a result of RIF-induced stimulation of hepatic cytochrome P450 
oxidase and glycoprotein transport systems, which can increase the metabolism of other 
administered medicines (Baciewicz et al., 2013). For example, RIF administered to patients 
already prescribed the blood thinner warfarin has been shown to cause hematuria (Martins et 
al., 2013).  
 
All of these drugs fall under the World Health Organisation (WHO) Group 1 category of 
drugs for the treatment of TB. 4 other groups (Table. 1) have been categorised, which are less 








Isoniazid (H); rifampicin (R); ethanbutol (E); 
pyrazinamide (Z) rifabutin (Rfb) 
 
Kanamycin (Km); amikacin (Am); capreomycin (Cm); 
viomycin (Vm); streptomycin (S) 
Group 3 
Fluoroquinolones 




Ethionamide (Eto); protionamide (Pto); cycloserine (Cs); 
teizidone (Trd); p-aminosalicylic acid (PAS) 
Group 5 
Agents with unclear role 
in DR-TB treatment (not 
recommended by WHO 
for routine use in DR-TB 
patients) 
Clofazimine (Cfz); linezolid (Lzd); 
amoxicillin/clavulanate (Amx/Clv); thioacetazone (Thz); 
imipenem/cilastatin (Ipm/Cln); high-dose isoniazid (high-






Table.1 WHO grouping of anti-TB drugs based on decreasing efficacy.  
Table taken from WHO (2008)!
 
1.4 Drug resistance in M. tuberculosis  
 
The current course of treatment for tuberculosis has been in place for around 50 years. 
Multiple factors have led to the relatively recent emergence of multidrug-resistant TB (MDR-
TB) and extensively drug-resistant TB (XDR-TB) strains. MDR-TB is defined as resistance to 
Rifampicin and Isoniazid, with second line (Group 2) drugs being employed for its treatment 
(WHO, 2013). XDR-TB strains are resistant to at least one Group 2 and Group 3 drug (Green 
& Garneau-Tsodikova, 2014). In 2012 there were an estimated 300,000 cases reported of 
MDR-TB, with 9.6% of these cases including XDR-TB (WHO, 2013). 
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Most resistance to Rifampicin arises from mutations in the rpoB gene encoding the beta-
subunit of RNAP, inhibiting enzyme-ligand complex formation (Campbell et al., 2001). 
Mutations in the INH-activating enzyme, KatG as well as in the gene and promoter region of 
its protein target, InhA are the most common causes of INH resistance (Ando et al., 2013). 
Group 2 and 3 based treatments for MDR-TB and XDR-TB are lengthy, coupled with the 
potential toxicity of the compounds and inaccessibility to treatments in less-developed 
countries has led to an increase in the prevalence of these strains in recent years (Green & 
Garneau-Tsodikova, 2014; WHO, 2013). Pyrazinamide resistance is associated with 
mutations in the gene coding for PncA. Specific mutations in the enzyme, including D8G, 
S104R and C138Y have been shown to render the enzyme inactive by creating a rigid binding 
cavity, preventing conversion of PZA to pyrazinoid acid (Rajendran et al., 2014). 
 
Several new drugs have been identified as potential treatments for drug-resistant TB. The 
Food and Drug Administration (FDA) recently approved one such drug, Bedaquiline, an 
inhibitor of bacterial ATP Synthase (Mahajan, 2013). By binding to the C-subunit of the ATP 
synthase F0 domain, Bedaquiline prevents the conformational change required for the 
production of ATP from ADP and PPi (Goel, 2014; Lakshmanan & Xavier, 2013). Another 
class of drugs, the Spectinamides, semisynthetic analogues of the antibiotic Spectinomycin, 
have recently been developed. Spectinamides show excellent antibacterial activity against 
nonreplicating M. tuberculosis by targeting 16S ribosomal RNA and are able to withstand 
efflux resistance due to the addition of a synthetic glycyl side chain (Lee et al, 2014). Other 
drug discovery efforts have focused on the high throughput screening of different compounds 
against M. tuberculosis, and have identified a class of compounds, the Dinitrobenzamides 
(DNBs) that target the oxidoreductase enzyme Decaprenyl-Phosphoribose 2’ Epimerase 




DprE1 is an essential enzyme for the survival of M. tuberculosis. Loss of this enzyme results 
in a phenotype characterised by swelling of the bacteria, leading to cell wall damage, lysis 
and death (Kolly et al, 2014). DprE1 is involved in cell wall biosynthesis, catalysing the 
conversion of decaprenylphosphoryl-D-ribose (DPR) to decaprenylphsphoryl-2-keto-β-D-
arabinofuranose (DPX), a keto-intermediate, which is then converted to 
decaprenylphosphoryl-D-arabinose by a second enzyme DprE2 (Fig. 2). DPA is required for 
the synthesis of arabinogalactan and LAM. There is no alternative pathway for the production 
of arabinan in Myobacterium, making DprE1 and DprE2 excellent drug targets for the 
treatment of TB (Christophe et al, 2009). DprE1 in particular has been shown to have an 
active site pocket to which certain small molecules can bind to with high affinity and inhibit 
enzyme function (Batt et al., 2012). 
 
 







1.6 Inhibitors of DprE1 
 
To date, at least 4 classes of compounds have been identified as inhibitors of DprE1. They are 
discussed below: 
 
Dinitrobenzamide (DNB) derivatives: Christophe et al., (2009), used confocal 
fluorescent microscopy to screen the effect of different compounds on the growth of GFP-
tagged M. tuberculosis in macrophages. They identified a large group of compounds that 
showed efficacy against M. tuberculosis, which shared a benzamide scaffold (Fig. 2). The 
minimum inhibitory concentration (MIC) of these DNB compounds was found to be as low as 
0.2 µM (for DNB1) and shown to be successful at killing drug-resistant strains of TB.  
 
Benzothiazinones (BTZs): BTZ compounds (Fig. 3) were initially involved in a large-
scale screen of compounds to identify those with antibacterial and antifungal properties 
(Makarov et al., 2006). One BTZ compound in particular, BTZ038, was selected for further 
study. The two enantiomers of BTZ038, named BTZ043 and BTZ044 were found to be 
equally as effective against M. tuberculosis, however BTZ043 showed the widest potency 
range across TB isolates, including drug-resistant strains (Makarov et al., 2009). BTZ043 was 
found to have a very low MIC against M. tuberculosis, around 1-4 ng/ml (Grover et al, 2014). 
In comparison, the MIC of Isoniazid, the most potent of the group 1 drugs, is around 0.03-
0.06 µg/ml (Guo, 2006). The low toxicity of BTZ043, coupled with its efficacy against drug-
resistant strains makes it a good candidate for treatment of MDR- and XDR-TB over current 
group 2 and 3 compounds (Pasca, 2010). BTZ043-resistant strains of Mycobacteria were all 
found to have amino acid substitutions at position 387 in DprE1, with the wild type cysteine 
residue replaced by Ser or Gly residues (Makarov et al., 2009). The x-ray crystal structure of 
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DprE1 in complex with another BTZ-derivative, CT325, provided evidence for the formation 
of a covalent bond between Cys387 and the compound (Batt et al., 2012), highlighting the 
importance of this residue for inhibitor binding.  
 
 TCA-1: A paper published by Wang et al., 2013 discusses the use of high-throughput 
assays to investigate the ability of compounds to inhibit biofilm formation in Mycobacterium 
smegmatis. One such molecule, TCA-1 (Fig.3C) was shown to inhibit this process in both M. 
smegmatis and M. tuberculosis. The same study used a TCA-1-resistant strain of M. 
smegmatis and a cosmid library to elucidate the target of TCA-1, which was found to be 
DprE1. The crystal structure of TCA-1 in complex with DprE1 was solved and a high level of 
similarity was observed between the binding nature of TCA-1 and BTZ043 to DprE1. TCA-1 
resistant M. tuberculosis mutants were found to have an amino acid substitution at position 
314 in Rv3790, with a Tyr replaced by Cys. 
 
Azaindoles: The 1,4-azaindoles are a class of compounds that were developed by 
scaffold morphing experiments of a known non-DprE1 targeting anti-TB compound based 
around an imidazo-pyridine scaffold structure. Shirude et al, 2014 modified the scaffold 
molecule three distinct points to optimize the inhibitory effect of the compound; the amide 
side chain, the hydrophobic group, and substitutions of the core ring structure. A secondary 
amide ring structure acts essentially to maintain a low MIC (Fig. 3D). In contrast to DNBs 
and BTZs, the azaindoles have been shown to interact with DprE1 noncovalently. 
Spontaneous mutations of amino acid 314 of Rv3790 (Y314H), the same residue implicated in 











 TCA-1  1,4-Azaindole 
  
Fig. 3 Four of the known classes of DprE1 inhibitors 
Structure of Benzothiazinone (A), Dinitrobenzamide (B) (Taken from Cole & Riccardi, 
2011.), TCA-1 (C; taken from Wang et al., 2013) and 1,4-Azaindole (D; taken from 









1.7 Previous work – DprE1 expression and purification 
 
Previous work on DprE1 and its inhibitors has led to a specific protocol for the purification of 
the protein. A plasmid construct to express M. tuberculosis DprE1 was achieved using the 
vector pCDF. The gene encoding DprE1, dprE1 (Rv3790) has been inserted into one of the 
multiple cloning sites (mcs) of pCDF.  Upstream of the mcs there exists a T7 promoter - a 
“strong” promoter highly specific for T7 polymerase. T7 and therefore DprE1 expression is 
under the control of the lac operator, allowing expression of the gene to be switched on in 
response to the addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG), an allolactose 
analog.  
 
The use of pCDF has allowed for the expression of a modified protein; containing a C-
terminal polyhistidine tag. The 6xHis tag expressed with DprE1 has a high affinity for nickel 
ions (Ni2+). A chelating agent such as Nitrilotriacetic acid (NTA), immobilised on agarose 
beads is used to fix Ni2+ to a column. Cell lysate is then run through the column and the His-
tagged protein will form bonds with the Ni2+ ions. Buffers containing a histidine analogue 
(imidazole) are then run through the column. A buffer containing a low concentration of 
imidazole can be used to elute proteins bound in a non-specific manner, i.e. those not 
expressing a His-tag, from the column. At sufficiently high concentrations, imidazole will 
compete with the Histidine tags for binding to Ni2+, displacing the tagged protein and eluting 
it. This is an effective method of isolating protein to a purity of up to!95% (Bornhorst & Falke, 
2000). A second chromatographic step, ion exchange chromatography is then used to mostly 
remove any remaining non-specifically bound proteins. This technique utilises the charge of 
the protein. The pH of the buffer can be altered to change the charge of the protein. When the 
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pH of the buffer is greater than the isoelectric point (pI), the protein achieves a net negative 
charge, and when pH<pI the net charge of the protein will be positive. M. tuberculosis DprE1 
has a predicted pI of 7.769 (not including 6 His tag; Tuberculist; Lew et al, 2011), so  a buffer 
of pH 8.5 has been used to establish a net negative charge on the protein. When passed 
through a column packed with strong anion quaternary ammonium (Q) ions immobolised on 
Sepharose beads, proteins in the solution will form ionic interactions with this stationary 
phase. Buffers containing increasing concentrations of NaCl are then passed through the 
column; the Na+ and Cl- ions disrupt protein-column interaction by competing with the 
charged functional group on the column. Different proteins will have varying isoelectric 
points and will therefore differ in the strength of their ionic interactions with the stationary 
phase. Weaker interactions will be broken at lower concentrations of NaCl, with more tightly 
bound proteins eluting at higher salt concentrations. 
Work published in Batt et al., 2012, investigated the effect that co-expression of DprE1 with 
molecular chaperones had on the amount of DprE1 recovered. Expression of DprE1 with the 
E. coli chaperonin GroEL and the M. tuberculosis GroEL homologue - Cpn60.1 with the E. 
coli cochaperonin GroES both yielded small amounts of soluble protein, however the two 
protein products could not be readily isolated from each other by chromatography. 
Coexpression with the essential M. tuberculosis chaperonin Cpn60.2 and the E. coli 
cochaperonin GroES yielded protein products that could be separated from one another, 







1.8 Aims and objectives  
 
DprE1 will be overexpressed in order to study the interaction of the protein with two of its 
known inhibitors. Ligand binding assays will be performed using fluorescence spectroscopy. 
DprE1 has intrinsic fluorescence due to the presence of fluorophores - compounds that can 
absorb light, exciting them to a higher energy level. The light emitted when a fluorophores 
returns to ground energy state is of a different wavelength to the light absorbed. This is due to 
energy being lost to the surroundings as vibrational energy (Möller and Denicola, 2002). 
Aromatic amino acids such as tryptophan and tyrosine give proteins natural fluorescence. 
DprE1 also contains a flavin cofactor group, which also acts as a fluorophore.  Within a 
fluorometer, a detector detects the fluorescence light emitted by a compound. Two 
monochromators allow the user to select the wavelengths of light the compound absorbs and 
the emitted wavelengths transferred to the detector. Different compounds exhibit different 
emission spectra. Fluorescence intensity is measured by the detector and can be used to 
determine the properties of ligand binding and the kinetics of the interaction. By performing 
titrations of the two known inhibitors with DprE1 we establish the dissociation constant (Kd) 
of the reaction, proportional to the affinity of the ligand for the protein.  
 
Previous efforts to determine the structure of DprE1 in complex with the compounds 1328 
and 1326 were unsuccessful. A homologue of DprE1 has been identified as a key component 
of the arabinofuranose pathway in Pseudomonas aeruginosa (Harvey et al, 2011). By 
establishing plasmid constructs for the overexpression of this homologue and the DprE1 
homologue from the related organism Mycobacterium smegmatis, we hope to develop an 
efficient method for the purification of these two proteins. Once purified, attempts to develop 
crystals of these proteins in complex with the two ligands will be possible.  
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2. METHODS 
2.1 Bacterial strains and plasmids 
Strains: 
Organism Strain Source 
E. coli BL21 (DE3) Invitrogen™ 
TOP10 Lab stock 
Mycobacterium smegmatis mc2155 Dr. Sarah Batt (University of 
Birmingham) 




Plasmid name Description Source 
pCDF-Rv3790 Plasmid for the expression of 
Mycobacterium tuberculosis 
dpre1 (Rv3790). The gene is 
under the control of a T7 
promoter and expressed with a 
C-terminal His-tag. An 
ampicillin resistance gene acts 
as a selectable marker. 









Plasmid containing the genes for 
the M. tuberculosis chaperonin 
Cpn60.2 (cpn60.2) and the E. 
coli cochaperonin GroES. 
Contains a spectinomycin-
resistance gene. 
Dr. Peter Lund (University of 
Birmingham) 
pCDF-Rv3790∆Y314C For the expression of a mutated 
form of M. tuberculosis dpre1 
(Rv3790) in which Cys387 has 
been substituted for Tyrosine. 
The gene is under the control of 
a T7 promoter and expressed 
with a C-terminal His-tag. An 
ampR gene acts as a selectable 
marker. 
Dr. Sarah Batt 
pCDF_MS_6382 For the expression of M. 
smegmatis dpre1 
(MSMEG_6382). The gene is 
under the control of a T7 
promoter and expressed with a 
C-terminal His-tag. An ampR 
gene acts as a selectable marker. 
This study 
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pCDF_psPA7_6248 Plasmid for the expression of 
Pseudomonas aeruginosa dpre1 
(Rv3790) homologue – 
PsPA7_6248. The gene is under 
the control of a T7 promoter and 
expressed with a C-terminal 
His-tag. An ampicillin resistance 









Forward primer for the PCR 
amplification of the dprE1 
(Rv3790) homologue from M. 
smegmatis (MSMEG_6382), 
with the introduction of an 
upstream SacI restriction site. 
DprE1_SM_Hind_RS CATGCATGAAGCTTTCAG
AGCAGTTGCAGGCGCCTG 
Reverse primer for the PCR 
amplification of the dprE1 
(Rv3790) homologue from M. 
smegmatis (MSMEG_6382), 
with a downstream HindIII 





Primer name Sequence (5’ to 3’) Description 
DprE1_PA_BamHI_FX CATGCATGGGATCCGATG
GAAGTCTTCGGCTGGGG 
Forward primer for the PCR 
amplification of the dprE1 
(Rv3790) homologue from P. 
aeruginosa (PsPA7_6248), 
with the introduction of an 




Reverse primer for the PCR 
amplification of the dprE1 
(Rv3790) homologue from P. 
aeruginosa (PsPA7_6248), 
with the introduction of a 





Forward primer for a site-
directed mutagenesis reaction 
to introduce a single 
nucleotide base pair in order to 
correct a deletion that had 












Reverse primer for a site-
directed mutagenesis reaction 
to introduce a single 
nucleotide base pair in order to 
correct a deletion that had 
occurred during the synthesis 
of pCDF_MSDPRE1 
 
2.3 Bacterial growth and media 
 
Luria-Bertani (LB) broth and terrific broth (TB) were both used for the overexpression of 
proteins in E. coli during this study. They were prepared as below. 
 
LB broth (1 L): 
• 10 g tryptone 
• 10 g NaCl 
• 5 g yeast extract 
Components were dissolved in 900 mL of deionized H2O and the pH adjusted to 7.2 using 
NaOH. The final volume was made up to 1 L and autoclaved at 121 °C for 15 minutes. 
 
LB agar (1 L): 




TB broth (900 mL): 
• 12 g tryptone 
• 24 g yeast extract 
• 4 mL glycerol 
 
TB salts (100 mL) 
• 2.6 g of KH2PO4 
• 13.9 g of K2HPO4 
 
Both TB broth and salts were autoclaved at 121 °C for 15 minutes. TB salts (100 mL) were 
added to the TB broth (900 mL) before use. 
 
2.4 Heat shock transformation of E. coli 
 
Competent cells were stored at -80 °C. Before use, a 50 µl aliquot of competent cells was 
allowed to thaw on ice for 5 minutes. Plasmids (1 µl each) were added directly to the 
competent cells and mixed gently by pipetting slowly up and down. The solution was left on 
ice for 30 minutes before being moved to a 42 °C water bath for 45 seconds. Immediately 
after heat-shock the tube was replaced on ice and left for 3 minutes. After 3 minutes, 250 µl of 
LB was added aseptically to the cells. Transformed cells were incubated at 37  °C, shaking at 
180 RPM for 1 hour. After this time, 100 µl of cells were taken and plated on an LB agar 
plate containing the appropriate antibiotic. In case of poor transformation efficiency the 
remaining cells were pelleted by centrifugation (14000 RPM, 10 minutes), resuspended in 100 
µl of LB and plated on LB agar supplemented with antibiotic. 
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2.5 Overexpression of M. tuberculosis DprE1 
 
The plasmids pCDF_Rv3790 and pTrc-60.2-GroES were transformed into E. coli BL21 
(DE3) competent cells (Invitrogen) by heat shock as described in section 2.4. Single colonies 
were picked from the plate using a sterile tip and used to inoculate 50 ml of LB media 
supplemented with 100 µg/ml Spectinomycin, 100 µg/ml Ampicillin and 1% glucose. The 
inoculated media was then incubated overnight at 37°C, 180 RPM in a shaker incubator.  
Overnight LB culture (10 ml) was added to a 2 L conical flask containing 1 L of terrific broth 
(TB) supplemented with 100 µg/ml Spectinomycin and 100 µg/ml AMP and grown at 37°C 
until an OD600nm of 0.4-0.6 was reached. At this point the cultures were placed at 4°C for 1 
hour, allowing them to cool before the addition of 0.5 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG). Induced cultures were then grown at 16°C overnight in a 
shaker incubator before cells were harvested at 4°C by centrifugation (4000 RPM, 30 mins). 
Pellets were resuspended and washed in a 1X phosphate buffered saline (PBS) solution before 
further centrifugation (4000 RPM, 30 mins, 4°C). Pellets were then either frozen at -80°C or 
resuspended in 30 ml Buffer A/Lysis buffer (50 mM NaH2PO4.H20, 300 mM NaCl, 10 mM 
Imidazole, pH8). An EDTA-free protease inhibitor mixture (Roche) and a small amount of 
FAD were added to each 30 ml sample. Cells kept on ice were then subject to lysis by 
sonication (Sonicator Ultrasonic Liquid Processor XL; Misonix) for 10 cycles of 20 s - on, 40 
s - off. Crude cell extract was then centrifuged at 20,000 RPM, 4°C for 40 minutes to separate 
the soluble and insoluble cell fractions. Supernatant was then filtered through a 0.45 µm 





2.6 Affinity chromatography 
 
A Ni-NTA affinity chromatography column (1 ml Histrap HP; GE Healthcare Life Sciences) 
was set to a flow-rate of 1 ml/min. The column was washed with 5 column volumes (cv) of 
filtered deionised H2O before being equilibrated with 5 cv of Buffer A. The filtered lysate was 
then loaded on to the column before 30 ml of wash buffer (50 mM Imidazole in Buffer A 
framework, pH8) was passed over the column. Protein was eluted using elution buffer 
(300mM Imidazole in Buffer A (see section 2.5, p.22), pH8). Fractions were analysed using 
SDS-PAGE electrophoresis (Mini-PROTEAN precast gel; BIO-RAD). Samples containing 
proteins of the same molecular weight as DprE1 were dialysed into buffer B (20 mM Tris.HCl, 
10mM NaCl, 10% Glycerol, pH 8.5). Alternatively, to avoid dialysis, after running the 30 
mM Imidazole wash buffer, 10 ml of buffer B was run through the column before elution with 
buffer C (20 mM Tris.HCl, 10 mM NaCl, 300 mM Imidazole, pH8). Glycerol (10%) was then 
added to the buffer C-DprE1 solution. 
 
2.7 Ion-Exchange chromatography 
 
Deionised H2O (5 cv) was used to wash a strong anion exchange column (1 ml HiTrap Q HP; 
GE Healthcare Life Sciences) before equilibration with Buffer B (5 cv). Dialysed DprE1 
solution was then loaded on to the column before buffers with varying NaCl concentrations of 
20 mM steps in a gradient from 100-140 mM (Buffer B framework) were passed through the 
column. A final high salt buffer (500 mM NaCl, buffer B framework, pH8.5) was used to 
remove any remaining protein bound to the column. Fractions containing DprE1 (as 
determined by SDS-PAGE electrophoresis) were dialysed into Buffer B.  
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2.8 Concentration of protein 
 
Protein concentration was measured by absorbance spectrophotometry at 280 nm (Nanodrop 
2000 UV-Vis Spectrophotometer; Thermo Scientific) against a reference sample of buffer B. 
Increasing the concentration of protein in the solution was achieved by filter centrifugation 
(30 kDa cut-off ULTRA-4 filter tubes; Amicon). Double-deionised H2O (4 ml) was added to 
each tube and centrifuged at 4000RPM for 10 minutes. Flow through was discarded and 4 ml 
of Buffer B was added to each tube and centrifuged again at 4000 RPM for 10 minutes. 
Finally dialysed protein solution (4 ml) was added to each tube and spun for 20 minutes, 4000 
RPM at 4 C 
 
2.9 Fluorescence Spectroscopy  
 
DprE1 was diluted to a concentration of 30 mM using buffer B. Fluorescence was measured 
using a PTI fluorometer (PTI Quanta Master 40) with power set to 75 Joules. Samples were 
loaded into a quartz cuvette with a path distance of 1 cm. Temperature was maintained at 
20°C by a liquid cooling system and a magnetic stirrer ensured homogeneity of the sample. 









2.10 Design of plasmid constructs for the expression of M. smegmatis and P. aeruginosa 
DprE1 homologues 
 
Primers were designed (see methods 2.2) for the amplification of DprE1-coding genes from M. 
smegmatis and P. aeruginosa to include flanking restriction endonuclease sites. For M. 
smegmatis, the forward primer (DprE1_SM_Sac_F) was designed to introduce a SacI site 
upstream of the M. smegmatis DprE1-coding gene (MSMEG_6382) and the reverse primer 
(DprE1_SM_Hind_RS) was designed to introduce a HindIII site downstream of the gene. 
 
 
PCR reaction mixtures (50 µl) were composed of: 
 
Component Concentration 
Deionised H2O variable 
5X Phusion HF Buffer 1X 
10 mM dNTPs 200 µM each 
Forward primer (10 pM/ml) 0.5 µM 
Reverse primer (10 pM/ml) 0.5 µM 
Template DNA variable 
DMSO 3% 







PCR program:  
 
Step Temperature (°C) Time (min:sec) No. of Cycles 
Initial denaturation 98 05:00 x1 
Denaturation 98 00:20 
x40 Annealing 60 or 65 00:30 
Extension 72 00:30 
Hold 4 ∞ ∞ 
 
 
PCR products were run on 1% Agarose gel stained with Midori Green (5 µl per 100 ml 
Nippon Genetics Europe) to confirm the presence of amplified genes. 
 
pCDF plasmid DNA (obtained from Dr. Sarah Batt; University of Birmingham) was 
transformed into E. coli TOP10 cells by heat shock treatment. Cells were plated on LB agar 
plates supplemented with 100 µg/ml SPEC and grown overnight at 37 °C. Colonies were 
picked and used to inoculate 5 ml of 100 µg/ml SPEC LB in cell culture tubes (BIO-RAD) 
and grown overnight at 37 °C in a shaker incubator. Plasmid DNA was purified from 
overnight cultures using a QIAprep Spin Miniprep Kit (QIAGEN).  
 
Restriction double digest was performed by mixing 30 µl of purified plasmid or PCR product 
DNA with 5 Vector of 10x buffer (NEB), 2.5 µl of each restriction enzyme (NEB) and 10 µl 
of ddH2O. Each sample was then incubated at 37 °C for 1 hour. Restriction products were run 
on 1% Agarose gel stained with midori green. The gel was visualised using near-UV (Helixx 
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LED Viewer) to avoid DNA damage and the bands of interest excised using a scalpel. DNA 
was purified using QIAquick Gel Extraction Kit (QIAGEN) before pCDF vector DNA was 
treated with Antarctic Phosphatase (NEB) to prevent re-circularisation. DNA concentration 
was measured by UV spectrophotometry at 260nm (Nanodrop 2000).  
 
Insert and vector DNA were mixed in a ratio of 3:1, calculated using the following equation: 
 
Amount of insert (ng) = 
Amount of vector (ng) × size of insert (kb) 
× 
3 
Size of vector (kb) 1 
    
Ligation reaction was performed using 1 µl of Quick-Stick DNA ligase, 5 µl of 4x Quick-
Stick buffer (Bioline) with the final reaction volume adjusted to 20 µl with ddH2O.  A 
control-construct containing only vector DNA was also made using the same protocol. The 
ligation reaction was allowed to proceed for 10 minutes before constructs were transformed 
into E. coli One Shot TOP10 chemically competent cells (Invitrogen). 100 µl of each sample 
was plated onto separate 100 µg/ml SPEC LB agar before the remaining samples were 
centrifuged (14000 RPM, 10 minutes). Supernatant was discarded and pellets were then 
resuspended in 100 µl of LB and plated on 100 µg/ml SPEC LB agar. Colonies were picked 
and used to inoculate 5 ml of 100 µg/ml SPEC LB in 10 ml cell culture tubes and grown 
overnight at 37 °C in a shaker incubator. Plasmid DNA was purified from overnight cultures 
using a QIAprep Spin Miniprep Kit. A second restriction double digest was performed on the 
purified plasmids to confirm the composition of the constructs. Plasmids were sent for 
sequencing (Eurofins MWG Operon) using the primers from the initial amplification of the 
DprE1 genes.  
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2.11 Site-directed mutagenesis of M. smegmatis pCDF_MSMEG_6382 construct 
 
Two oligonucleotide primers were designed for the introduction of the deleted base in M. 
smegmatis C4 by site-directed mutagenesis; Mutagenesis was performed using the 
Quickchange II XL kit (Angilent technologies). Reaction was set up as follows: 2.5 µl of 10X 
reaction buffer, 2.5 µl of a 1/10 dilution of pCDF-DprE1 DNA, 1 µl of each primer (1/10 
diluted), 0.5 µl dNTPs, 1.5 µl of Quiksolution and 16 µl of ddH2O. Finally 1 µl of PfuUltra 
HF DNA Polymerase was added. The sample was placed in a thermal cycler and run using the 
program: 
Step Temperature (°C) Time (min:sec) No. of Cycles 
Initial denaturation 95 01:00 x1 
Denaturation 95 00:50 
x18 Annealing 60 00:50 
Extension 68 06:00 
Final extension 68 07:00 x1 
 
Once the PCR program had completed, 1 µl of the enzyme DpnI was added to the sample. 
This was then centrifuged for 1 minute at 14000 RPM on a tabletop centrifuge before being 
incubated for 1 hour at 37 °C. The mutated construct was then transformed and cultured in E. 
coli TOP10 cells as before. Plasmids were purified and sent for sequencing using the primers 






2.12 Small scale expression studies of pCDF_PsPA7_6248 
 
Both PA7 pCDF-DprE1 and pTrc-60.2-GroES plasmids were transformed into E. coli BL21 
(DE3) cells by heat-shock and plated on LB agar (100 µg/ml SPEC and 100 µg/ml AMP). A 
colony was then used to inoculate 50 ml of LB (100 µg/ml SPEC and 100 µg/ml AMP) and 
grown overnight at 37 °C, 180 RPM. From this, 500 µl was used to inoculate 50 ml of terrific 
broth (100 µg/ml SPEC and AMP) in 250 ml shake flasks. Six t-broth cultures were grown at 
37 °C until reaching the required OD600nm (0.4, 0.6 and 0.8), at which point they were 
transferred to 4 °C and cooled for 20 minutes. Each culture was induced with 0.5 mM IPTG 
and then one of each OD 0.4, 0.6 and 0.8 culture was grown at 16 °C and 25 °C overnight. 
Cultures were then transferred to a 50 ml falcon tube and centrifuged at 4000 RPM for 30 
minutes at 4 °C. Supernatant was discarded and pellets were resuspended in 10 ml of Buffer 
A, pH 8.5. Cells were sonicated on ice (20-s on, 40-s off) for 4 cycles. 1 ml of each crude 
lysate was transferred to an eppendorf tube and centrifuged at 14000 RPM, 4 °C for 10 
minutes. 10 µl of each lysate, insoluble and soluble fractions were mixed with 2.5 µl of 4X 











2.13 Western blot analysis of BL21 (DE3) pCDF_PsPA7_6248 small-scale expression 
fractions 
 
Using a BIO-RAD Mini Trans –Blot Cell, an SDS-PAGE gel from the small-scale expression 
study of PA7 was placed on a nitrocellulose filter and then sandwiched between two filters 
and sponges. The cell was then placed in an electrophoresis tank containing 1 L of Transfer 
Buffer (25 mM Tris, 200 mM Glycine, 10% (vol/vol) Methanol) and run for 1 hour at 20 V, 
300 mA. The nitrocellulose membrane was then transferred to a gel tray and washed with a 
TBS-Tween (20 mM Tris, pH7.5, 150 mM NaCl, 0.05% (vol/vol) Tween) with 5% (w/v) milk 
powder solution for 30 minutes on a rocker. TBS-Milk solution was poured away and the 
membrane was washed with 50ml TBS-Tween for 5 minutes, 3 times, discarding the solution 
in between each. The membrane was then soaked in 50 ml of TBS-Tween solution with 0.1% 
milk powder and 50 µl (1:1000) of the primary antibody (monoclonal anti-polyHistidine 
antibody produced in mouse; Sigma-Aldrich). After 30 minutes the solution was discarded 
and 3 washes of 5 minutes each with TBS-Tween were performed. A 50 ml solution of TBS-
Tween with 2 µl (1:20000) of secondary antibody (Anti-Mouse IgG; Sigma-Aldrich) was next 
added to the membrane and mixed for 30 minutes. Two further 5-minute washes with TBS-
Tween were performed, followed by a wash with TBS (no Tween-20).  Finally, a 10ml 
solution of 5-bromo-4-chloro-3-indolyl phosphate (BCIP; 1 tablet in 10 ml of ddH2O; Sigma-
Aldrich) was poured over the membrane. The reaction was left to proceed for 5 minutes, or 








3.1 Overexpression and purification of Mycobacterium tuberculosis DprE1 
 
Expression of Mycobacterium tuberculosis DprE1 had previously been shown to be improved 
by co-expression with the chaperone molecules GroEL from E. coli and Cpn60.2 from M. 
tuberculosis (Batt et al, 2012). Two plasmid constructs; pCDF-Rv3790 and pTrc-60.2-GroES 
were transformed in to (heat shock) competent E. coli BL21 (DE3) cells. Selected for cells 
containing the plasmid on Spectinomycin with Ampicillin LB agar plates.  Cells were then 
grown, protein production induced and cultures harvested (see Methods), before affinity 
chromatography was performed. Fig. 4 shows different stages of the chromatography. An 
intense band visible in the lane with the flow-through suggests that not all DprE1 was 
successfully bound to the column.. The wash stage with Buffer A -50 mM imidazole (for 
buffer composition see page 24) led to slight elution of DprE1 as seen in lane 4, whilst the 
majority of protein is eluted with the 300mM imidazole buffer. Protein eluted from the Ni-
NTA column was dialysed to reduce the salt concentration to ensure binding to the QHP 
column. This step appeared to result in a slight loss of protein (Fig. 4B, Lane 2). An 
alternative protocol was used after this, which negated the need for the dialysis step and the 
associated protein loss incurred with the additional protocol step. The eluate from the HisTrap 
column was then loaded through the QHP ion exchange column. All DprE1 bound to the 
QHP column as shown in the difference between lanes 2 and 3 in Fig 4B. Washing the 
column with 100 mM NaCl (in buffer B framework; Section 2.5) failed to elute any DprE1 
(Fig. 4). Increasing the concentration to 120 mM NaCl initiated the elution of DprE1, albeit 
slowly (Fig. 4). The majority of DprE1 eluted at 140 mM NaCl with the remainder leaving the 
! 31!
column at 500 mM NaCl. Fractions containing DprE1 were combined and then dialyzed into 
a low NaCl buffer (based in buffer B framework; Section 2.5). 
A B 
 
Fig. 4 (A) Ni-NTA chromatography of M. tuberculosis DprE1. Lanes from left to right 
contain mass standard (1), cleared lysate (2), initial flow through (3), 50 mM imidazole buffer 
eluate (4) and 300 mM imidazole buffer eluate (5). (B) Ion exchange chromatography of M. 
tuberculosis DprE1. Lanes from left to right contain mass standard (1), Ni-NTA eluate (2), 
initial flow through (3), 100 mM NaCl eluate (4), 120 mM NaCl eluate (5), 140 mM NaCl 
eluate (6), 500 mM NaCl eluate (7) 
 
Protein was then concentrated by ultrafiltration, with a final concentration of 1.8 mg/ml. 
Successive purification and concentration attempts utilizing the alternative protocol resulted 




3.2 Ligand binding assays 
 
3.2.1 Principles of Fluorescence 
Fluorescence is the re-emission of light by a molecule 
in response to the absorption of a photon. Fluorescent 
compounds, called fluorophores initially exist in a 
base state where electrons are in an energy level 
within the ground state (Fig.6 S0). When exposed to a 
photon these fluorophores become excited and move 
from the ground state to an energy level in the excited 
electronic state (Fig. 6 step 1). Over a period of time, 
known as the fluorescence lifetime, vibrational relaxation causes the fluorophore to lose 
energy in the form of heat to its surroundings or kinetic energy/vibration (Fig. 6 step 2, S1’ to 
S1). Finally, transition to the ground state causes the release of energy in the form of a photon 
(Fig 6. step 3). Due to the loss of energy in step 2 the wavelength of the emitted photon 
(hνEM) is longer than that of the incident photon that caused the initial excitation (hνEX). The 
relationship between energy and wavelength is described by the equation: E = hc/λ, where E = 
energy, h = Planck’s constant (6.6260755 x 10¯34 Joule second), c = the speed of light (2.998 
x 108 m/s) and λ = wavelength of the light. This shows that the energy of a photon is inversely 
proportional to its wavelength. 
 
Fig. 5 DprE1 post-concentration. 
Lanes: mass standard (left), 
DprE1 post-concentration (right) 
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Fig.6 Jablonski diagram 
showing the three basic steps 
of electron movement during 
the process of fluorescence. 
(1) Photons (hνEX) cause the 
excitation of the fluorophore to 
a higher energy level (S1’) 
from the ground state (S0). (2) 
Vibrational relaxation causes 
the loss of a small amount of 
energy and the fluorophore 
moves to a lower energy level 
yet still remains within the 
excited state (S1). (3) The 
fluorophore returns to the 
ground state releasing a photon 
of a different 
wavelength/energy (hνEM) to 
that involved in step 1 (hνEX). 
h = Planck’s constant 
(6.6260755 x 10¯34 Joule 
second), ν = frequency. 
(Johnson & Spence, 2010) 
 
The photons involved in fluorescence can be detected using a machine known as a fluorimeter, 
which also measures their relative intensities. The concentration of a fluorophore is directly 
proportional to fluorescence intensity. Proteins can exhibit intrinsic fluorescence due to the 
presence of the aromatic amino acids; tryptophan, tyrosine and phenylalanine. Tryptophan 
fluorescence is the most commonly measured due to its sensitivity to its environment and 
high quantum yield (Kraft et al., 2009; Φ = #photons emitted/#absorbed). The intensity of 
fluorescence can therefore be dependent on changes in fluorophore environment such as 
protein folding, conformational changes or ligand binding. This makes fluorescence 
spectroscopy a good tool for the study of protein interactions. 
AstraZeneca provided two inhibitors of DprE1, named 1326 and 1328. The company did not 
disclose the chemical structures of these two compounds. To determine the binding affinity of 
these inhibitors fluorescence spectroscopy was performed.  
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Determining the maximum excitation and emission wavelengths of DprE1 and ligands 
 
Initial scans were performed on a reference sample of buffer B. The results of an excitation 
scan of the reference sample revealed clear peaks with high intensities, indicative of 
contaminants. The glycerol was removed from the buffer and the aforementioned peaks 
disappeared, indicating the glycerol was responsible for the prior abnormal readings. Fig. 7 
shows the excitation scan of DprE1 revealing a max excitation point of ~280 nm. Emission 
scans of a solution of buffer B (no glycerol; section 2.5) containing 1 µM DprE1 determined a 
max intensity at the wavelength 328 nm (Fig.8). An emission scan was also performed on a 
solution of buffer B and 1328 revealing a broad peak of intensity, overlapping somewhat with 




Fig. 7 Excitation scan of 1 µM DprE1 from 200-300 nm. Max intensity was determined to be 





























Fig. 8 Emission spectra (300-400 nm) of DprE1 (1 µM; green) and 1328 (8 µM; red) with a 
fixed excitation wavelength (280 nm). The maximum emission wavelength of DprE1 was 
found to be ~328 nm. 1328 emitted maximally at a wavelength of  >415 nm. The overlapping 
of these two spectra meant that excitation at 280 nm would be unsuitable to ascertain a precise 
value of intensity if both DprE1 and 1328 were present in the same solution. Slit width = 0.6 
mm 
 
The excitation wavelength was decreased to 270 nm in an attempt to try and separate the 
ligand and protein peaks, but as the titration in Fig. 9 shows there was still a fair amount of 
interference between the two, making it hard to discern the intensity of emission at 425 nm 
particularly in samples with low concentrations of 1328. However, the increase in emission 
















































Fig. 9 Emission spectra (300-500 nm) obtained upon titration of 1328 into DprE1 with an 
excitation wavelength of 270 nm. At this wavelength the emission peaks of both enzyme and 
inhibitor still influence one another. DprE1 shows a peak emission at ~330 nm and 1328 at 
~425 nm. Slit width = 0.6 mm 
 
Fig. 10 The increase in intensity of peak emission wavelength observed at 425 nm with 











In an attempt to separate the two intensity peaks at 425 nm and 328 nm new emission scans 
were performed for DprE1, this time exciting at a wavelength characteristic of the flavin co-
factor, FAD. The excitation wavelength maximum for the flavin was determined to be 448 nm 
with peak emission intensity observed at 525 nm. Following on from this, an emission scan of 
the reference sample, buffer B excited at 448 nm revealed an unknown peak with a maximum 
intensity at 530 nm.  Varying the excitation wavelength from 450 nm to 460 nm shifted this 
peak by a value proportional to the change in wavelength (Fig. 11), suggestive of the Raman 
effect. DprE1 (1 µM) was added and the excitation wavelength was again varied from 450 to 
460 nm (Fig. 10). By increasing the excitation wavelength to 460 nm the two peaks were 




Fig. 11 The effect of varying excitation wavelength on the Raman peak observed in the 
emission spectra (480-580 nm) of a reference sample (Buffer B; Section 2.6) excluding ligand 
or protein. Excitation wavelength was found to be proportional to the emission wavelength of 













































Fig. 12 The effect of varying excitation wavelength from 450 nm to 460 nm on the Raman 
peak observed in the emission spectra (480-580 nm) of 300 µl Buffer B + 1 µM DprE1. The 
shift in Raman peak emission wavelength maximum is proportional to the change in 
excitation wavelength. At an excitation wavelength of 460 nm a separation between Raman 
peak and FAD emission peak at ~520 nm is observed. Key refers to excitation wavelength. 
Slit width = 0.6 mm 
 
Titrations of 1328 were performed at 460 nm. Fig. 13 shows the binding curve of a titration of 
1328 into 2 µM DprE1 in increments of 2.5 µM. No saturation appears even at a ligand to 
protein ratio of 30:1. By this point it was expected that no further increase in fluorescence 
would be observed. Saturation occurs when all protein is bound to the ligand. The linear 
nature of the graph was suspected to be as a result of oxidation of flavin, which displays 
different fluorescence characteristics than reduced flavin (Ghisla, 1980). To test this, 2 µM 
DprE1 was excited at a wavelength of 460 nm at time intervals over a 4 hour periodcourse 
was measured. The intensity of the peak maximum increased linearly over a 4 hour time 
period, showing no sign of saturation (Fig. 14). In order to prevent this and continue working 




























oxygen. The limitations of the equipment available prevented this approach. Instead, it was 
proposed that rather than titrating ligand into protein, protein could be titrated into ligand, and 
therefore avoiding the high initial concentration of DprE1 that would be subject to oxidation. 
 
Fig. 13 Titration of 1328 from 0-55 µM in to an initial concentration of 2 µM of DprE1. 
Values correspond to the emission peak maxima recorded at the wavelength of 520 nm. Slit 
width = 0.6 mm 
 
 
Fig. 14 The change of intensity observed in the FAD emission peak at wavelength 520 nm in 
a sample of DprE1 over time. A linear increase in intensity is observed proportional to an 

































Previous emission scans of 1328 revealed an emission maximum at a wavelength of 
approximately 415 nm (as shown in Fig. 8) when excited at 280 nm. The excitation 
wavelength however, was increased to 297 nm to overcome the influence of the emission 
peak at 330 nm (from tryptophan residues). 1328 (10 µM) was established and DprE1 was 
titrated in to the sample in 0.2 µM increments. However, by the time 0.6 µM DprE1 had been 
added intensity values were over 600,000 counts, over the threshold for efficient detection by 
the fluorimeter. To circumvent this, the slit width of the fluorimeter monochromators was 
decreased from 0.6 mm to 0.4 mm, to allow less light to pass and therefore decrease the 
intensity of the detected fluorescence. Further readings were taken and intensity values well 
under 600,000 were recorded (Fig. 15). 
  
Fig. 15 Emission spectra (315-500 nm) of DprE1 (0-4.25 µM) titrated into initial 10 µM of 
1328. Excitation wavelength for this experiment was 297 nm. The red line at the bottom of 
the graph is representative of the baseline 10 µM 1328. An emission wavelength peak is 
















Fig. 16 Titration of DprE1 in to 10 µM 1328. By ~4 µM DprE1 peak emission signal 
intensity begins to saturate. Data has been corrected to account for the change in [1328] with 
increase in total sample volume. Mean Kd = 0.638 (±0.06) µM and a Bmax= 154,581 (±10,316) 
The interaction displayed single site saturation binding behavior (Fig. 16); with a calculated 
mean Kd = 0.638 (±0.06) µM and a Bmax= 154,581 (±10,316). Titrations were repeated with 
1326 under the same parameters. 1326 displayed a different emission spectra, with maximum 
intensity observed at a wavelength of ~365 nm (Fig. 17). 
 
Fig. 17 Emission spectra (315-500 nm) of DprE1 (0-4.25 µM) titrated in to 10 µM 1326. 
Excitation wavelength was fixed at 297 nm. The yellow line at the bottom of the graph 















































Titration of DprE1 in to 1326 (Fig. 17) displayed a similar single site binding characteristic as 
observed in titrations with 1328. The experiments were performed in triplicate and mean Kd of 
1.24 (±0.479) µM and a Bmax of 459763 (±61619) were calculated (Fig.18). 
 
Fig. 18 Titration of DprE1 in to a concentration of 10 µM of 1326. Fluorescence intensity was 
recorded over the wavelength range 315-500 nm with peak intensity varying wavelength 
between 360 and 367 nm (see Fig. 17). Excitation wavelength was fixed at 297 nm. Mean Kd 
= 1.24 (±0.479) µM, Bmax = 459763 (±61619), across 3 replicates. 
Interestingly, the emission peak wavelength of the spectra shifted from 360 nm to 367 nm as 
concentration of DprE1 was decreased (Fig. 19). 
 




























































































Negative control titrations of bovine serum albumin (BSA) in to 1326 & 1328 
A negative control for both 1326 and 1328 was performed using bovine serum albumin 
(BSA). Unlike DprE1, BSA was predicted to not display any interaction with the two 
compounds and therefore no increase in emission maxima at either 415 nm (for 1328) or 365 







Fig. 20 The emission spectra of 0.25-5 µM bovine serum albumin (BSA) titrated in to 10 µM 
1326. Excitation wavelength = 297 nm. An emission peak is observed at ~330 nm, 

































As Fig. 20 shows, with increasing concentrations of BSA an increase in fluorescence was 
observed at ~330 nm, but not at 415 nm (for 1328) or 365 nm (for 1326) as seen in figures 15 
and 17, respectively. This increase in fluorescence at 330 nm is indicative of tryptophan 
residues found in BSA and is proportional to the overall increase in concentration of BSA in 
the solution.  
 
Negative control titration of mutated DprE1 ∆Y314C into 1326 & 1328 
 
A further set of control titrations were performed substituting DprE1 for a mutated form of 
the protein in which the amino acid tyrosine at position 314 had been mutated to cysteine. 
This protein is found in M. tuberculosis mutants resistant to the inhibitors TCA1 and those of 
the azaindole class and is therefore highly implicated in DprE1 inhibitor resistance (Batt et al., 
2012). The titration experiments were repeated using DprE1 Y314C with 1326 and 1328 and 
showed similar single site binding saturation properties to the unmodified protein (Fig. 21). 

























































Fig. 21 (A) Titration of DprE1 Y314C (0 – 3.25 µM) in to 10 µM 1328. An excitation 
wavelength of 297 nm was used. Emission peak wavelength was recorded at ~420 nm. The 
experiment was performed in triplicate the and mean Kd = 0.21 µM, Bmax = 152,958, (B) 
Saturation binding curve of 1326 with a titration of DprE1 Y314C. An excitation wavelength 
of 295 nm was used. Emission peak wavelength was recorded at a range between 360 and 367 
nm. Mean values for Kd = 0.69 µM and Bmax = 457,074 were established after the experiment 
was performed in triplicate (no error estimates available). 
 
! 46!
Although fluorescence spectroscopy is a useful tool in providing information as to whether 
protein and ligand interact it isn’t always accurate and doesn’t provide information on the 
exact mechanism of binding. If a conformational change in the protein is associated with 
ligand biding this can lead to the introduction of a quenching group in to the vicinity of the 
fluorophore and directly influence the intensity detected (Royer & Scarlata, 2008). This in 
turn would affect the calculated values for Kd and Bmax. In order to determine exactly if and 
how protein ligand interactions occur a structural technique such as x-ray crystallography 
could be employed. 
 
3.3 Generation of DNA plasmid expression constructs encoding recombinant Pseudomonas 
aeruginosa and Mycobacterium smegmatis DprE1 homologues 
 
Previous efforts to crystallise M. tuberculosis DprE1 with 1328 were successful. However, 
upon subjecting the crystals to x-ray scattering, the ligand was not detectable in the electron 
density map. In order to try and determine the binding mechanism of these inhibitors with 
DprE1 two homologues of the protein were chosen. From Mycobacterium smegmatis, 
MSMEG_6382, which shares 84.4% sequence identity to Rv3790, and from Pseudomonas 
aeruginosa PA7, PsPA7_6248, which shares 33% sequence identity to Rv3790. 
Oligonucleotide primers (obtained from Eurofins MWG Operon) were designed for the PCR 
amplification of the two homologues from gDNA isolated from the two species. Each primer 
was designed to include a different restriction endonuclease site to flank the amplified gene. 
These restriction enzymes were selected based on their presence in the multiple cloning site 
(MCS) of the plasmid pCDF. SacI and HindIII were chosen for PA7 and BamHI and NotI for 
M. smegmatis. PCR reactions were performed on gDNA from both species with two variable 
annealing temperatures, 60 °C and 65 °C to determine which was most effective for 
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amplification. For M. smegmatis gene amplification was observed at 60 °C, but not at 65 °C, 





Fig. 22 Agarose gel (1%) showing the products of PCR amplification of MSMEG_6382 and 
PsPA7_6248. Lanes from left to right contain mass standard, M. smegmatis 60 °C, M. 
smegmatis 65 °C, PA7 60 °C, PA7 65 °C. (Given temperatures refer to annealing temperature 
of reaction used). Expected size of product band = ~1.5 kb 
 
 
The PCR reaction was repeated with PA7 gDNA using a gradient thermal cycler (Touchgene 
Gradient; Techne Limited) varying the annealing temperature of the reaction from 50 °C to 
70 °C across 12 steps. Product was formed at an annealing temperature of 63 °C (Fig. 23).  
 
Fig. 23 Agarose gel analysis of PsPA7_6248 amplification from PA7 gDNA using an 
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PCR products were then subjected to treatment with restriction enzymes (SacI and HindIII for 
PsPA7_6248 and BamHI and NotI for MSMEG_6382). The plasmid vector, pCDF was also 
digested with each pair of restriction enzymes. Digested DNA samples were run on agarose 
gel and viewed using a near-UV viewer to confirm digestion. Bands of interest were 
identified and then excised using a sterile scalpel. DNA was purified from the gel slices 
before the sample of vector DNA was treated with antarctic phosphatase to remove 5’ 
phosphates, preventing self-ligation. Vector and insert DNA were mixed in a ratio of 3:1 and 
ligated.  
A control sample with only vector DNA was produced using the same protocol. All samples 
were transformed into E. coli TOP10 cells and selected overnight on LB agar supplemented 
with Ampicillin. Transformation efficiency of PA7 constructs was low, with only 2 colonies 
appearing on the plate after 16 hours incubation time. Colonies were also present on the PA7 
control plate suggestive of vector circularization. Colonies from both PA7 and M. smegmatis 
construct plates were cultured and plasmid DNA was purified. A second restriction digest was 
performed on the purified DNA to confirm the presence of both insert and vector DNA. Fig. 
24 shows the result of this second digestion. Four out of 7 M. smegmatis (Lane 1-4) colonies 
digested to reveal vector and insert bands. Neither of the PA7 samples showed a band 







Fig. 24 Agarose gel analysis of second restriction digest to identify successful ligation of 
vector and insert DNA. Lanes from left to right: mass standard (M), M. smegmatis constructs 
(1-7) and PA7 constructs (8 and 9). Successfully ligated vector and insert constructs are 
shown in lanes 1-4. 
 
The multiple band pattern displayed in lane 8 (Fig. 24) is typical of circular plasmid DNA. 
The other PA7 construct sample (lane 9) showed a single band for vector DNA but no band 
for insert DNA. Circular plasmid DNA and a single vector band suggested that full digestion 
hadn’t been achieved. Homologous recombination of the plasmid DNA could explain these 
results by the removal of one (lane 9) or both (lane 8) restriction sites. Construction of the 
PA7 construct was repeated using two new samples of digested vector DNA but yielded 
similarly disappointing results. Repeating the amplification of DprE1 and increasing the insert 
to vector ratio to 9:1 also gave no result. All vector DNA previously used had been purified 
and digested from one sample of TOP10 cells transformed with pCDF. The issue of 
recombination would have likely arisen at this point, subsequently affected all following 
results. The protocol was repeated by a colleague (Dr. Sarah Batt), who was able to achieve 
the correct construct displaying clear vector and insert bands upon a second digestion with 
restriction enzymes. No explanation can be given for the previous failed attempts. 
 
!!!!!!!!!!M!!!!!!!!!!!!1!!!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!4! !!5! !!!6! !!!!!7! !!!!!8! !!!!!!9!
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Both plasmids were sequenced against the PCR primers used to originally amplify the DprE1 
genes. Both showed base substitutions toward the 3’ end of sequence data. However, 
sequencing of both DNA strands using the forward and reverse primers revealed these to be 
artifacts of cloning. All M. smeg sequences revealed either one or two nucleotide deletions, 






Fig. 25 Sequence alignment between sequenced M. smegmatis constructs and the wild-type 
MSMEG_6382 DNA sequence. (A) 1391delC, (B) 1386delC, 1402delC. In both alignments 
the stop codon of the wild type MSMEG_6382 gene is the TGA that ends at position 1407. 
 
Primers were designed to reintroduce the deleted Cytosine base at position 1391 by site 
directed mutagenesis. Once carried out, mutated constructs were transformed into TOP10 











3.4 Overexpression and purification of PA7 and M. smegmatis DprE1 homologues from 
constructs 
 
Initially, both constructs were transformed and grown in E. coli BL21 (DE3) cells using the 
same protocol as for M. tuberculosis DprE1 overexpression. The theoretical isoelectric point 
(pI) of both proteins was calculated using ProtParam (Gasteiger et al, 2005; 
http://web.expasy.org/protparam/). The pI of M. smegmatis DprE1 was predicted as 6.47 and 
the PA7 DprE1 pI as 8.19. Buffers used for the purification of M. tuberculosis DprE1 had 
been pH 8. Although suitable for the purification of the M. smegmatis protein, the pH of the 
buffers used to purify PA7 DprE1 was increased to 9.25 to avoid precipitation of the protein.  
 
M. smegmatis DprE1: 
Due to the high amino acid sequence similarity between M. tuberculosis and M. smegmatis 
DprE1 homologues it was decided that the protocol adapted for the purification of M. 
tuberculosis DprE1 would be suitable for the M. smegmatis homologue. M. smegmatis DprE1 
behaved very similarly to M. tuberculosis DprE1, eluting at a concentration of 300 mM 
imidazole. However, a small amount of protein was also found in the 50 mM imidazole wash 
buffer fraction. Once loaded on to the QHP column, DprE1 was found initially in the 120 mM 
NaCl buffer fraction, and also in the fractions from the 140 mM and 500 mM NaCl buffer 
fractions. The protein was concentrated to ~ 6.7 µg/ml but lacked the intense yellow colour 
associated with the oxidised flavin cofactor, which is typical of the M. tuberculosis protein.  
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Fig. 25 SDS-PAGE gel of samples from the Ni-NTA (left) and QHP (right) chromatography 
of M. smegmatis DprE1 preperation. (Left) Lanes contain, from left to right; mass standard 
(M), cleared lysate (1), initial flow through (2), 50 mM imidazole buffer flow through (3), 
buffer B flow through (4), 300 mM imidazole buffer (low salt) flow through (5). (Right) 
Lanes contain, from left to right; Mass standard (M), Ni-NTA eluate (1), initial flow through 
(2), 100 mM NaCl buffer flow through (3), 120 mM NaCl buffer flow through (4), 140 mM 
NaCl buffer flow through (5), 500 mM NaCl buffer flow through (6). 
 
PA7 DprE1: 
BL21 (DE3) cells were transformed with the pCDF_psPA7_6248 plasmid and grown. Once 
induced, grown and harvested cells were lysed. Lysate was cleared and then loaded on to the 
Ni-NTA column. At this stage M. tuberculosis lysate appears yellow in colour but the lysate 
from the pCDF_psPA7_6248 cells was colourless. After passing the lysate through the 
column, buffers containing 50 mM and 300 mM imidazole were subsequently passed through. 
Analysis of the eluted fractions by SDS-PAGE indicated that all protein was eluted in the 50 
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mM imidazole buffer wash stage (Fig. 26, left, lane 3). After dialysis, the Ni-NTA eluate was 
loaded through the QHP column. Bands suspected to be DprE1 were observed initial flow 
through and thought to also be in the fractions of 120 mM and 140 mM NaCl buffers  (Fig. 26, 
right, lanes 4 & 5). The eluate from 120 and 140 mM NaCl fractions were dialysed to a low-
salt buffer before the protein was concentrated to ~ 6 µg/ml. Unlike the M. smegmatis protein 
purified, the PA7 protein displayed the typical yellow colour of DprE1. The purified protein 
was then aliquoted in to 96-well trays with the hope of forming protein crystals. However, 
after 2 weeks, no significant results were seen. 
 
Fig. 26 SDS-PAGE gel of samples from the Ni-NTA (left) and QHP (right) chromatography 
of PA7 DprE1. (Left) Lanes contain, from left to right; mass standard (M), cleared lysate (1), 
initial flow through (2), 50 mM imidazole buffer flow through (3), 300 mM imidazole buffer 
flow through (4). (Right) Lanes contain, from left to right; Mass standard (M), Ni-NTA eluate 
(1), initial flow through (2), 100 mM NaCl buffer flow through (3), 120 mM NaCl buffer flow 
through (4), 140 mM NaCl buffer flow through (5), 160 mM NaCl buffer flow through (6), 
200 mM NaCl buffer flow through (7), 500 mM NaCl buffer flow through (8). 
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3.5 Small-scale expression studies to optimize the expression of pCDF_PsPA7_6248 
To try and optimise the expression of PA7 DprE1 a series of small-scale expression 
experiments were carried out. Two variables were set; time of induction and growth 
temperature post-induction. BL21 (DE3) cells transformed with pCDF_psPA7_6248 were 
induced at three different points; upon reaching either OD600 nm 0.4, 0.6 or 0.8 and then grown 
overnight at either 16 °C or 25 °C. These temperatures were chosen as they are determined to 
be the best range for the overexpression of recombinant proteins in BL21 (DE3) (Rosano & 
Ceccarelli, 2014). Once harvested, cells were sonicated and a sample of crude lysate was 
centrifuged to separate soluble and insoluble fractions. Gel electrophoresis of these fractions 
showed that 25 °C appeared to be a more effective temperature for expression of DprE1 (Fig. 
27). 
 
Fig. 27 SDS-PAGE analysis of lysate fractions induced at variable temperature; 16 °C and 
25°C. Gels show samples of crude lysate (L), soluble fraction (S) and insoluble fraction (I) of 
different cultures of BL21 (DE3) pCDF_psPA7_6248 induced at different OD600nm readings 
(0.4, 0.6 or 0.8) and then grown overnight at either 16 °C (left) or 25°C (right) 
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3.6 Western blot analysis of BL21 (DE3) + pCDF_PsPA7_6248 lysate fractions 
 
Western blot analysis of the gels was then performed on gels identical to those shown in Fig. 
28 (non-stained). An antibody specific to the His-tag located at the N-terminal end of the 
recombinant DprE1 was used to locate which fraction the protein was located in. The PA7 
DprE1 homologue was revealed to be in both the lysate and insoluble fraction, but not the 




Fig. 28 Western blot analysis of lysate fractions induced at variable temperature; 16 °C and 
25°C. Gels show samples of crude lysate (L), soluble fraction (S) and insoluble fraction (I) of 
different cultures of BL21 (DE3) pCDF_psPA7_6248 induced at different OD600nm readings 
(0.4, 0.6 or 0.8) and then grown overnight at either 16 °C (left) or 25°C (right). Gels were 








































Many studies have identified DprE1 as the target of a number of inhibitors effective at killing 
M. tuberculosis cells. As a target, DprE1 stands at the forefront of the drug-discovery effort 
for the treatment of TB, of which multiple drug-resistant strains now exist. DprE1 plays a key 
role in the growth of Mycobacteria, being required for the synthesis of arabinan, one of the 
components of the Mycobacterial cell wall, essential for the survival and persistence of M. 
tuberculosis. This study investigated the interaction between DprE1 and two of its inhibitors. 
 
4.1 Purification of DprE1 
 
The purification process of M. tuberculosis DprE1 was associated with some loss of the 
protein of interest (Page 30, Fig.4, lane 3). Western blot analysis could be used to confirm the 
presence of DprE1 in the flow-through sample and perhaps recycling of the flow-through 
back through the column would encourage more protein-column interactions. 
 
4.2 Fluorescence spectroscopy of DprE1-inhibitor interactions 
 
Ligand-binding assays were effective at determining the dissociation constants (Kd) of the two 
compounds tested. 1326 was found to have a mean Kd of 0.355 µM, whilst 1328 was found to 
have a higher mean Kd of 0.638 µM over 3 replicates. In contrast, the benzothiazinone 
compound BTZ043 has been previously shown to have a lower Kd value of 0.1462 µM (Batt 
et al., 2012) in DprE1 titrations, therefore having a higher affinity for DprE1 than the two 
compounds tested in this study. BSA was used as a negative control to confirm that increase 
in fluorescence was due only to DprE1-inhibitor interactions and not as a result of increased 
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levels of protein in vitro. With increasing protein to ligand ratio a red shift in wavelength of 
the peak was observed. This effect has been well documented for the fluorescence of 
Tryptophan residues, which display solvatochromism, meaning the wavelength of their 
emission peak is highly dependent on the polarity of their environment (Park, Kim & Bark, 
2002). The emission peak wavelength shift observed in the case of 1326 could be due to the 
changing of functional groups on residues in DprE1 stimulated by inhibitor binding 
(Gasymov & Glasgow, 2008). The fact this bathochromic shift (i.e. to a longer wavelength) is 
observed in titrations involving 1326 but not 1328 might suggest the specific binding 
mechanisms of each to DprE1 are different.  
 
4.3 Purification of DprE1-homologues from M. smegmatis and P. aeruginosa 
 
M. smegmatis DprE1 was purified with moderate success. Like M. tuberculosis DprE1, 
affinity chromatography resulted in a small loss of protein in the 50 mM Imidazole wash. 
Decreasing the imidazole concentration of the wash buffer might help to prevent this DprE1 
loss, whilst still being effective at removing non-specific proteins from the column. Purified 
M. smegmatis DprE1 showed signs of FAD reduction, appearing colourless, however the 
exact reducing agent is not known. This reduction of may allow spectroscopic titrations to be 
performed at flavin emission wavelengths, as the linear increase in intensity over time 
associated with flavin oxidation may not be seen.  Incubation of reduced-DprE1 with FAD 
could be tried in order to re-oxidise the flavin group.  
 
PA7 DprE1 mostly resided in the insoluble fraction upon centrifugation of lysed cells. This is 
most likely due to its incorporation in inclusion bodies, dense aggregates of denatured protein, 
which cannot be purified under standard conditions (Singh & Panda, 2005). Incorporation of 
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protein into inclusion bodies is dependent on chaperone molecules (Hwang, Pan & Sykes, 
2014). Expression of PA7 pCDF_PsPA7_6248 without the co-expression of the chaperonin 
Cpn60.2 and co-chaperonin GroES might prevent or limit the formation of these insoluble 
inclusion bodies. Lysis and fractioning of these cells followed by western blot analysis of 
each would reveal if this omission of chaperones has any effect. Conversely, co-expressing 
PsPA7_6248 with different chaperonin molecules, including GroL and GroS from P. 
aeruginosa, might yield better results. IPTG concentration has also been implicated in the 
formation of inclusion bodies during recombinant protein induction, with lower 
concentrations generally inducing protein at a slower rate and therefore generally increasing 
protein solubility (Tolia & Joshua-Tor, 2006).  
Purification of inclusion bodies can be performed under denaturing conditions. Urea or 
similar is used to isolate the inclusion bodies before a strong denaturant and reducing agent 
e.g. β-mercaptoethanol or DTT are used to solubilise the protein (Lilie, Schwarz & Rudolph, 
1998). Protein must then be refolded but this is not always achievable and often does not 
result in the natural state of the protein. (Peti & Page, 2007). The reducing agent would also 
change the redox state of the flavin cofactor and make performing fluorescence spectroscopy 
experiments and measuring flavin excitation difficult. 
 
4.4 Further work 
 
Due to the difficulties associated with the structure determination of DprE1 in complex with 
1326 and 1328 and the potentially long time frame of this approach other experiments could 
be performed along side.  
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Determination of the MIC of the two compounds would allow their efficacy to be tested 
directly on M. tuberculosis cells either on their own, or in combination with other anti-TB 
compounds. This can be achieved using in vitro activity assays by incubating bacterial 
cultures of known cfu with the inhibitor(s) and monitoring their effect after a given period of 
time. Bacteria of different species could also be tested to determine the specificity of the 
compounds. 
An accompanying set of experiments could be performed to force the evolution of inhibitor-
resistant strains of Mycobacteria. As a preliminary, evolution could either be investigated in   
M. smegmatis or M. bovis BCG due to the highly similar DprE1 homologues expressed in this 
organisms. This would forgo the need for a category 3 lab, and should also be more efficient 
due to the generation time of M. smegmatis being significantly lower than that of M. 
tuberculosis. Generation of mutants requires selection by incubating cells with a 
concentration of inhibitor above that of the MIC of susceptible cells (MICsusc) but below that 
of resistant bacteria (MICres). This is known as the mutant selective window hypothesis 
(Gullberg et al., 2011). Inhibitor-resistant mutants can then be sequenced and any amino acid 
mutations in the DprE1-coding gene noted. Amino acid changes would most likely be 
indicative of key residues required for formation of enzyme-ligand complex. Expressing the 
altered gene sequence in a plasmid construct would then allow for the purification of any 
mutant DprE1 proteins identified. Purified mutant DprE1 could then be used to repeat the 
titration experiments described in this study. If resistance to the inhibitory compounds is as a 
result of the specific amino acid changes then no increase in fluorescence at the compound-







This study has used fluorescence spectroscopy to determine the Kd values of two inhibitors of 
the essential M. tuberculosis enzyme, DprE1. Titrations with an Y314C mutant form of the 
enzyme has showed that this amino acid change does not diminish the binding affinity of the 
inhibitors, indicating that they interact with DprE1 via a different mechanism to the azaindole 
and TCA-1 class of inhibitors. Mean Kd values of 0.355 µM and 0.638 µM were determined 
for 1326 and 1328, respectively. Efforts to produce efficient plasmid constructs for the 
expression of DprE1 homologues from M. smegmatis and P. aeruginosa were largely 
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The chaperonins are a distinct class of molecular chaperones. Mycobacteria contain 
multiple chaperonins, coded for the cpn genes; cpn60 and cpn10 homologous to E. 
coli groEL and groES, respectively. Both cpn10 and cpn60.2 have been found to be 
essential, whilst cpn60.1 is dispensable. Mutants lacking cpn60.1 have been shown to 
be deficient in biofilm formation and the ability to establish granulomas in 
Mycobacterium smegmatis and Mycobacterium tuberculosis, respectively. 
Mycobacterium marinum has been established as an excellent model system for the 
study of TB infection due to its relative safety, ease of use and fast growth rate 
compared to M. tuberculosis. M. marinum also has the advantage of available animal 
infection systems in Danio rerio  for the study of in vivo phenotype. Here we 
investigate the phenotype of a ∆cpn60.1 mutant of M. marinum. Loss of Cpn60.1 
appears to convey an advantage to heat-shock; possibly due to an up-regulation of 
Cpn60.2. ∆cpn60.1 mutants also show an altered lipid profile with increased 
expression of one cell wall component. Overall, these results support the evidence 
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Mycobacteriaceae is a vast family of bacteria belonging to the order Actinobacteria. The 
Mycobacteria are non-motile and Gram-positive based on their phylogeny and lack of outer 
cell membrane.  However, unlike other gram-positive bacteria, the mycobacteria do not retain 
the crystal violet dye used in gram staining and are therefore defined as being acid-fast. This 
is due in large part to their thick, lipid-rich cell walls. The morphology of Mycobacteria varies 
from rod-like to filamentous (Bruijnesteijn van Coppenraet, 2009).  
 
Of the Mycobacteriaceae family, three species are known to be human pathogens: 
Mycobacterium tuberculosis, Mycobacterium ulcerans and Mycobacterium leprae, the 
etiological agents behind tuberculosis (TB), Buruli ulcers and leprosy, respectively.  A 
number of other Mycobacteria are non-human pathogens such as Mycobacterium bovis, 
which is the causative agent in bovine tuberculosis. Most of the pathogenic Mycobacteria are 
classified as slow growing, taking 7 days or more to form colonies visible to the naked eye. 
However, there is no direct correlation between growth rate and pathogenicity (Hett & Rubin, 
2008). Another group, termed the fast growing Mycobacteria, including Mycobacterium 
smegmatis and Mycobacterium marinum, tend to be non-pathogenic or opportunistic 






1.1.1. Mycobacterium tuberculosis 
 
It’s estimated that one third of the world’s population is a carrier of M. tuberculosis. The 
World Health Organisation (WHO) estimates that in 2012, 8.6 million people developed 
active tuberculosis, of which 1.3 million cases were fatal (WHO, 2014). Mycobacterium 
tuberculosis and its sub-species form the Mycobacterium tuberculosis complex (MTBC), 
which are responsible for tuberculosis across a number of host species.  Members of the 
MTBC are evolutionarily related, originating from a common ancestor, estimated to be ~2.5 
million years old, based on evolutionary data (Fig. 1; Galagan, 2014). 
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1.1.2. M. tuberculosis mode of infection 
 
M. tuberculosis is an air-borne pathogen, entering the host via the respiratory system in air 
droplets called droplet-nuclei. If these cells then reach the alveoli of the lungs they activate 
the release of interleukin-12 (IL-12) by dendritic cells and become ingested by macrophages, 
a response triggered by gamma-interferon (IFN-γ) release from CD4+ T helper 1 (Th1) cells 
(Flynn, 2004). This immune response leads to the formation of a granuloma, resulting in the 
stage of M. tuberculosis infection known as latent tuberculosis. Bacteria can persist inside the 
macrophage for decades (Lillebaek et al., 2003), by preventing the development of 
macrophage phagosome to a bacterial phagolysosome. This is achieved by the inhibition of 
macrophage Ca2+ signaling - M. tuberculosis inhibits the enzyme sphingosine kinase, a key 
component of the Ca2+/calmodulin signaling pathway (Kushner, 2005).  
The switch from latent to active TB is known as reactivation and can be brought about by a 
number of factors including, but not limited to; immune failure, HIV, or in response to 
antibiotic treatment  (Flynn & Chan, 2001). During reactivation, dormant bacteria are released 
from the granuloma as the result of macrophage apoptosis. From here the bacteria can 
establish pulmonary tuberculosis (67% of U.S. cases in 2011; CDC, 2013) or enter the 
bloodstream, where they can establish infection in another part (extrapulmonary TB) or 
multiple parts (miliary TB) of the body. M. tuberculosis relocation to the central nervous 
system results in a form of TB named tuberculous meningitis. 
 
1.1.3. Survival and virulence of M. tuberculosis 
 
The survivability and virulence of M. tuberculosis is in a large part due to its complex cell 
wall. All Mycobacteria share a common waxy, lipid-rich cell wall, with varying degrees of 
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thickness, contributing to their acid-fast staining nature. Antibiotic-resistant strains of M. 
tuberculosis have significantly larger cell walls (Veleyati et al., 2009), highlighting the 
importance of these structures in cell survival. Multiple components comprise the 
Mycobacterial cell wall. Peptidoglycan, arabinogalactan and mycolic acids make up the cell 
wall core mycolyl-arabinogalactan-peptidoglycan (mAGP) complex. The peptidoglycan layer 
is composed of repeating units of β-(1-4)-linked N-acetyl glucosamine-N-acetyl muramic acid 
(NAG-NAM) bonded together with peptide bridges. This layer is the target of antibiotics such 
as penicillin, but these have no efficacy in mycobacteria due to the impermeability of the 
mycolic acid layer. Arabinogalactan surrounds the peptidoglycan layer, comprised of 
arabinan-tagged galactan. The arabinan is branched and can be subjected to modifications 
such as the addition of non-N-acetylated galactosamine, which may have a role in 
pathogenesis (Škovierová et al, 2010). The arabinogalactan acts as an anchor for the mycolic 
acid layer to which it is attached via ester bonds. These are long-chain (C60-C90) α-alkyl β-
hydroxy fatty acids formed of a saturated α-branch chain attached to a longer meromycolate 
chain (≥C56). The mycolic acids can be subdivided into three classes according to the different 
modifications present on the meromycolate chain; alpha-, methoxyl- and keto-mycolates. 
Fatty acid synthase-I (FAS-I) and FAS-II are the key components in the mycolic acid 
biosynthesis pathway. FAS-I synthesizes the initial short chain (C26) fatty acid chain from 
acetyl-CoA, whilst FAS-II synthesizes the meromycolate (C56) chain (Takayama, Wang & 
Besra, 2005; Bhatt et al., 2007). One of the components of FAS-II, the elongation-condensing 
enzyme, KasB has been shown to be essential for virulence. ∆kasB knockout strains of M. 
tuberculosis have been shown to persist in, but did not display pathogenicity toward 
immunocompetent mice (Bhatt et al., 2007). Mycolic acid modifications are also important 
for dampening the host immune response. Strains deficient in the certain mycolic acid 
methyltransferases (MAMTs) responsible for mycolate cyclopropanation show an increased 
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sensitivity to the host immune response, becoming attenuated one or two weeks post infection 
(Barkan et al., 2012). Another key factor, Trehalose 6,6′-dimycolate (cord factor) has been 
shown to induce a granulomatous response when injected into rat corneas (Saita et al., 2000). 
Overall the Mycobacterial cell wall is fundamental to the survival and pathogenicity of M. 
tuberculosis, and any factors that affect this key structure can have drastic consequences.  
 
1.1.4. Drug resistance in M. tuberculosis 
 
Mycobacterium tuberculosis infection is currently treated with a combination of 4 first-line 
drugs (FLD); Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB) and Pyrizinamide 
(PZA). A number of second and third line anti-tubercular drugs are also used in combination 
when a poor patient response to the first-line drugs is observed. However, these show 
decreased efficacy against TB and often have side effects leading to poor patient compliance. 
The drug regimen of TB is very strict, with a minimum treatment time course of a 6-month. 
Development of the disease is more prolific amongst immunocompromised patients, such as 
those who are HIV-positive and are 12-20 times more at risk  (WHO, 2014). These factors, 
coupled with non-diagnosed cases and poor access to anti-TB treatment have led to the 
emergence of antibiotic-resistant strains of TB. Multi drug-resistant tuberculosis (MDR-TB) 
strains are resistant to one or more of the FLDs. Strains that are non-responsive to treatment 
with all FLDs and at least one second-line drug are known as extensively drug-resistant 
(XDR-TB).  Reports of totally drug-resistant tuberculosis (TDR-TB) were first noted in Italy 
in 2004. Since then, numerous cases have been reported, with patients showing no response to 
all first and second-line drugs (Parida et al, 2014). The majority of current TB research has 
therefore been focused on identifying anti-TB compounds and their targets. 
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1.1.5. Mycobacterium marinum as a model system for TB-study 
 
Mycobacterium marinum is primarily a pathogen of ectotherms, in which it causes a TB-like 
infection with the establishment of granulomas. It also has a well-documented opportunistic 
pathogenicity towards humans. Due to its low optimal growth temperature, infection in 
humans is usually limited to extremities, such as hands and feet, but has also been shown to 
establish infection in other areas (Benton & Karkanevatos, 2007). M. marinum is the closest 
evolutionary relative to the members of the M. tuberculosis complex (see Fig. 1.1; Cronan & 
Tobin, 2014). 3000 orthologous genes are shared between M. marinum and M. tuberculosis 
with an average amino acid identity of 85% (Stinear et al., 2008). Many of these orthologues 
are virulence genes, with a number of M. tuberculosis genes able to complement a mutant 
gene in M. marinum (El-Etr et al., 2004). Unlike M. tuberculosis, a biosafety level 3 (BSL-3) 
pathogen requiring specialist equipment and laboratories, M. marinum is a BSL-2 pathogen 
and can be worked with safely on the bench top. M. marinum also has the advantage of being 
a relatively fast growing member of the Mycobacteria genus with a doubling time of 4-6 
hours (without antibiotics), compared to the 20 hour doubling time of M. tuberculosis (Barker 
et al., 1999). Numerous animal model systems are available for M. marinum infection assays. 
Hosts such as Drosophila melanogaster and Dario rerario (zebrafish) have been used for the 
study of anti-tubercular drugs and disease pathogenesis (Takaki et al., 2013; Oh et al., 2013). 
These animal systems have the advantage of being cheap, easily genetically manipulated, 
having a rapid life cycle, and generating large numbers of offspring. Zebrafish also have the 
added benefit of being translucent at the embryonic stage, allowing in vivo imaging of 




1.2. The chaperonins of E. coli 
 
The chaperonins are a sub-class of molecular chaperones, and can be divided into two types; 
type-I and type-II. Type-II chaperonins are found in archaea and the eukaryotic cytosol and 
are self sufficient, not requiring a co-chaperonin to function (Horwich et al., 2007). Type-I 
chaperonins are homologous to GroEL in E. coli. GroEL, along with the co-chaperonin 
GroES, are coded for by the groE genes. Discovery of the groE genes in the early 1970s 
resulted from inhibition of bacteriophage growth as a direct result of their mutation 
(Friedman, 1992). Although classically thought of as heat-shock proteins, GroEL and GroES 
were also shown to be essential for growth at low temperatures in E. coli (Fayet et al., 1989). 
The function of these proteins was initially brought to light upon discovery that they are 
homologous to proteins essential for the correct folding of Rubisco, a key part of the 
photosynthetic process in plant chloroplasts (Hemmingsen et al., 1988). This was confirmed 
when overexpression of GroEL and GroES were shown to aid in the in vitro refolding of un-
folded Rubisco (Gouloubinoff et al., 1989). Around 5% of E. coli proteins interact with 
GroEL (Azia et al., 2012). Roughly 300 proteins are substrates of GroEL, of which 85 are 
GroEL-dependent and 15 are essential for cell viability (Lund, 2009). 
 
The induction of GroEL-GroES during the heat-shock response is dependent on the gene 
rpoH, which encodes the alternative sigma factor, σ32 (Guisbert, et al., 2004). Increases in 
temperature lead to a destabilization of an RNA structural element, which under normal 
conditions serves to inhibit σ32 transcription (Morita et al, 1999). The concentration of σ32 
under normal conditions is also dependent on negative regulation by the proteins DnaK, DnaJ 
and GrpE. Strains mutated for dnaK, dnaJ or grpE show increased levels of σ32 at 30°C 
(Straus et al., 1990).  These three proteins collectively form the DnaK chaperone system 
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responsible for promoting ATP-dependent protease degredation of σ32 (Suzuki et al., 2012). 
σ32 acts as a transcription factor to direct RNA polymerase to specific promoters, including 
the groESL operon (Cowing & Gross, 1989). A second σ70-dependent promoter also lies 
upstream of the groESL operon leading to low-levels of transcription of GroEL and GroES 
under normal conditions, in line with their secondary housekeeping role (Zhou et al., 1988).  
 
1.2.1. Structure and the GroEL ATPase cycle 
 
GroEL (also known as hsp60) comprises fourteen 57 kDa protomers arranged as two 
symmetrical seven-member rings, referred to as the cis and trans rings ,(Saibil et al., 2013). 
Each protomer can be divided into three domains; an equatorial domain and an apical domain 
connected by a smaller intermediate domain. Each protomer contains an ATP-binding pocket 
located in the equatorial domain, essential for function (Roseman et al., 1996). The apical 
domains form a large hydrophobic ring essential for binding of polypeptides and GroES, with 
which GroEL forms a complex (Fenton et al., 1994). The GroEL reaction is initiated by the 
movement of the individual protomers between the apical and intermediate domains in 
response to ATP-binding (Braig et al., 1995). This is followed immediately by the binding of 
nonnative polypeptide to the cis ring. GroES displaces the polypeptide by binding to the cis 
ring, forming a “lid” like structure and forcing the polypeptide into the large 85 000 Å3 central 
cavity (Lund, 2009). GroES is comprised of seven 10 kDa subunits, within which β-strands of 
individual subunits interact with one another to stabilize a dome-like ring structure (Ikeda-
Kobayashi et al., 2012). A mobile loop at the opposite end of each subunit makes a 1:1 
contact with the hydrophobic region on the apical domain of an ATP-containing GroEL 
protomer (Saibil, et al., 2013). Binding of GroES stimulates a conformational change in 
GroEL as the hydrophobic surface on the apical domains is shifted and replaced with a 
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hydrophilic surface (Xu et al., 1997). The environment created by the binding of GroES 
allows the nonnative protein to refold, unhindered. Binding of ATP to the trans ring releases 
the newly folded protein and ADP from the cis portion of GroEL (Lund, 2009). Overall, the 
GroEL-GroES-ATP7 complex promotes refolding of denatured proteins by isolating them 
from non-permissive conditions and introducing them to an environment without external 
hindrances (Lin & Rye, 2006). This model of chaperonin-mediated refolding is known as the 
Anfinsen cage, named for the nobel prize-winning biochemist Christian B, Anfinsen. 
 
1.3 The multiple chaperonins of Mycobacteria 
 
Around 30% of all bacteria have more than one copy of GroEL (Lund, 2009), suggestive of a 
divergence in function. The Mycobacteria contain genes homologous to groEL and groES, 
named cpn60 and cpn10, respectively. Most Mycobacteria have more than homologue of 
cpn60. Initial phylogenetic analysis of groEL genes across all bacteria revealed two distinct 
clades (Fig. 1.3; Rao  & Lund, 2010; Goyal et al., 2006). These are given the nomenclature 
GroEL1 (cpn60.1), and GroEL2 (cpn60.2). In Mycobacterium smegmatis a further gene 
named cpn60.3 is present. BLAST searches revealed the best-matched cpn60.3 homologue 
exists in Rhodococcus jostii, likely making it the result of a more recent horizontal gene 
transfer event (Rao & Lund, 2010). In all recorded cases cpn60.2 is present, whilst cpn60.1 is 
occasionally absent, hinting at its dispensable nature. This hypothesis was confirmed in M. 
tuberculosis (Hu et al., 2008), M. smegmatis (Ojha et al., 2005) and M. bovis BCG (Wang et 
al., 2011) in which ∆cpn60.2 mutants were non-viable. In the same three species ∆cpn60.1 
mutants were viable but displayed altered phenotypes (discussed later).  Phylogenetic analysis 
reveals that the GroES homologue, cpn10 is found in all Mycobacteria and is also 
indispensable (Hu et al., 2008). 
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In species with more than one cpn60 gene, cpn10 is found in an operon with cpn60.1, with 
cpn60.2 located elsewhere on the genome. When cpn60.2 is the only cpn60 gene, cpn10 exists 







The Cpn60 proteins can be characterised based on C-terminal amino acid consensus 
sequences. Cpn60.1 has a Histidine-rich C-terminus, and Cpn60.2 C-termini always contain a 
glycine and methionine-rich motif known as a GGM repeat. The relevance of these C-
terminal features is unknown, however Colaco & MacDougall, 2013 suggest a role for the 






Unlike E. coli GroEL, Cpn60.1 and Cpn60.2 do not form large multimeric complexes under 
standard conditions, but rather form lower oligomers (Qamra, Srinivas & Mande, 2004). Fan 
et al., 2012, used analytical ultracentrifugation (AUC) and showed that the molecular mass of 
eluted Cpn60.1 and Cpn60.2 proteins were much lower than that of GroEL, and confirmed 
this was the case using gel electrophoresis. They then went on to show that at high 
concentrations of salt and nucleotide Cpn60.2 formed high-order structures reminiscent of the 
tetradecameric structure of GroEL. This, coupled with the finding that Mycobacterial Cpn60.2 
proteins can replace E. coli GroEL in vivo (Hu et al., 2008; Fan et al., 2012), confirm that 





1.3.1 Induction of Mycobacterial chaperonins in the heat-shock response 
 
The Mycobacterial chaperonin genes all show an inverted repeat region upstream, known as a 
Controlling Inverted Repeat of Chaperone Expression (CIRCE) sequence (TTAGCACTC-N9- 
GAGTGCTAA-5’; Zuber & Schumann, 1994; Narberhaus, 2002). The regulatory protein, 
HrcA binds to CIRCE sequences, repressing the expression of CIRCE-regulated genes. In 
∆hspR∆hrcA double mutants of M. tuberculosis the expression of the chaperonin genes are 
upregulated. In the ∆hspR M. tuberculosis single mutant, only cpn10 is up-regulated, 
indicating cpn60.1 and cpn60.2 are regulated by HrcA, and HspR plays a role in the 
regulation of cpn10 (Stewart et al., 2002). HspR binds to a consensus sequence called HspR-
associated inverted repeats (HAIR). It has been shown that cpn60.1 and cpn60.2 (with DnaK) 
are required for the activation of HspR (Das Gupta et al., 2008), highlighting a possible 
positive feedback response for the expression of cpn10. The HspR-activated expression of 
cpn10 is consistent with the hypothesis that cpn60.1 and cpn10 might not be co-transcribed 
and their expression possibly regulated by two different mechanisms (Kong et al., 1993). 
 
1.3.2. The role of cpn60.1 in biofilm formation 
 
The multiple copies of cpn60 found in Mycobacteria have led to questioning of the potential 
moonlighting roles of the Cpn60 proteins. Moonlighting is a term used to describe the 
multiple roles that Cpn60.1 appears to play within different bacteria – a divergence of 
function away from the standard protein-folding role played by GroEL and Cpn60.2. Due to 
its non-essential nature, the role of Cpn60.1 has been studied through the creation of gene-
specific knockout strains. In a paper published in 2005, Ojha et al., found that in M. 
smegmatis, cpn60.1 is required for the formation of mature biofilms. The ability to form of a 
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biofilm is an evolutionary characteristic shared by many bacteria. By secreting an 
exopolysaccharide matrix, the bacteria are able to form self-containted communities 
protecting themselves from harmful external conditions.  M. tuberculosis is thought to form 
biofilms in vivo adding to its already high tolerance to antibiotic treatment (Islam et al., 2012). 
However, Hu et al., 2008 showed that Cpn60.1 was not required for the formation of biofilms 
in M. tuberculosis. In M. smegmatis ∆cpn60.1 mutants, synthesis of the C56-C68 long chain 
fatty acids typical of the Mycobacteria mycolic acids is absent, especially during biofilm 
formation. Cpn60.1 was shown to physically associate with KasA, the essential protein that 
forms part of the FAS-II complex discussed previously. This evidence suggests a key role for 
Cpn60.1 in the switch to biofilm formation by promoting mycolate synthesis. 
 
1.3.3 Immunomodulatory effect of the chaperonins 
 
Mycobacterial chaperonins have been implicated in the establishment of host immune 
response. Both Cpn60.2 and Cpn10 from M. tuberculosis have been shown to have 
immunomodulatory effects in guinea pigs, promoting the production of certain inflammatory 
cytokines (Friedland et al., 1993; van Eden et al., 2005). Likewise, Hsp65 (Cpn60.2) was 
shown to act as an antigen for T cell recognition in healthy humans, with the ability to react 
with Hsp65 from M. tuberculosis, M. bovis BCG and M. lepraea (Munk et al., 1989; Mustafa 
et al., 1993). M. tuberculosis ∆cpn60.1 mutants fail to elicit an immune response in guinea 
pig infection models (Hu et al., 2008), preventing the formation of granulomas. This appears 
to be a result of the multinucleated giant cell (MGC) -promoting activity of Cpn60.1 (Cehovin 
et al., 2010), highlighting the role of Cpn60.1 as a virulence factor essential for the 
establishment of TB. Cpn60.1 and Cpn10 have both been detected as secreted products in the 
supernatant of M. tuberculosis cultures (Cehovin et al., 2010; Fossati et al., 2003). In the 
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same study, Cehovin et al., show that Cpn60.2 was not detected in culture supernatant, but 
has been reported to be located on the cell surface along with the Hsp70, DnaK (Hickey et al., 
2009). Here, Cpn60.2 has been shown to bind to the glycoprotein, CD43, located on the 
surface of murine macrophages (Hickey et al., 2010). By binding to CD43, Cpn60.2 might act 
as a signal for phagocytosis of cells  (as seen in Streptococcus gordonii; Urano-Tashira et al., 
2008). 
 
1.4 Aims of this project 
 
Previous work in our lab has looked into the role of the chaperonin genes in Mycobacterium 
smegmatis, in particular their role in stress responses (Rao & Lund, 2009). However, as a 
non-pathogenic organism, there exists no infection model for M. smegmatis for in vivo study 
of phenotypes. The work of a previous MSc student, Farah Islam, led to the generation of a 
∆cpn60.1 mutant strain of Mycobacterium marinum by transposon phase mutagenesis 
(phAE181; Islam, unpublished).  
The main aim of this project will be to characterize the phenotype of this mutant strain. As 
Cpn60.1 appears to have a key role in mycolate synthesis, the lipid profile of ∆cpn60.1 strain 
will be compared to wild type to see the effect of Cpn60.1 loss. M. smegmatis cpn genes were 
shown to be upregulated in response to heat shock and of this will be investigated in M. 
marinum using heat-killing plating assays and qRT-PCR. If phenotype is observed in any 






2. MATERIALS AND METHODS 
2.1Bacterial strains and Plasmids 
2.1.1 Strains 
Organism Strain Source 
E. coli 
DH5α Lab stock 
MGM100 + pTrcESmmcpn60.1 This lab 
MGM100 + pTrcESmmcpn60.2 This lab 
M. smegmatis 
Mc2155 (Snapper et al., 1990) 
Mc2155 ∆cpn60.1 (Ojha et al., 2005) 
M. marinum 
WT + pMSP-dsRed This lab 
∆cpn60.1 This lab 
∆cpn60.1 + pMSP-dsRed This lab 
 
2.1.2 Plasmids 
Name Description Source 
pMSGroEL1 
M. smegmatis cpn10 + cpn60.1 -expressing plasmid 
derived from pMV361 
(Ojha et al., 2005) 
pMSGroEL2 
M. smegmatis cpn10 + cpn60.2 -expressing plasmid 
derived from pMV361 
(Ojha et al., 2005) 
pMS10.cpn60.2 
pMSGroEL1-derivative containing M. smegmatis 
cpn60.2 
(Rao & Lund, 2010) 
pMS10.cpn60.3 
pMSGroEL1-derivative containing M. smegmatis 
cpn60.3 
(Rao & Lund, 2010) 
pMS10.groEL pMSGroEL1-derivative containing E. coli GroEL (Rao & Lund, 2010) 
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2.2 Oligonucleotide primers 
Name Sequence (5’ to 3’) Description 
Mm_cpn10_F GCGAAGGTGAACATCAAG
CCA 
Forward primer for qPCR-detection of  
M. marinum cpn10 
Mm_cpn10_R AGGAATGACCAGACCGGA
CG 
Reverse primer for qPCR-detection of  





Forward primer for qPCR-detection of  





Reverse primer for qPCR-detection of  





Forward primer for qPCR-detection of  





Reverse primer for qPCR-detection of  
M. marinum cpn60.2 
Mm_gapdh_F CCTACACCCAGGACCAGAA
C 
Forward primer for qPCR-detection of  
M. marinum gap 
Mm_gapdh_R ATCACCAGACCGATGGCTT
T 
Reverse primer for qPCR-detection of  
M. marinum gap 
MS_cpn10_R AGGTACTCCTCGCCGTTGT
A 
Reverse primer with affinity to  
M. smegmatis cpn10 for upstream 






2.3 Bacterial growth media 
 
For Mycobacteria strains: 
Liquid Media: Middlebrook 7H9 broth (Difco; BD) supplemented with 10% OADC and 0.5% 
Tween-80 
 
Solid Media: Middlebrook 7H10 agar (Difco; BD) supplemented with 10% OADC 
 
Antibiotics: wild type strains were grown in the presence of 50 µg/ml Kanamycin. ∆cpn60.1 
strains were grown in the presence of both 50 µg/ml Kanamycin and 100 µg/ml of 
Hygromycin. 
 
For E. coli : 
LB was used for both solid and liquid culturing. 
 
Antibiotics: E. coli transformants were grown in the presence of 50 µg/ml Kanamycin.  










2.4 M. marinum growth curves 
 
Frozen -80 stocks of M. marinum strains were streaked on 7H10 agar plates supplemented 
with OADC and appropriate antibiotics and grown at 30 °C until single colonies formed. In 
25 mL universal tubes, 5 mL 7H9 growth media was inoculated with a single colony of M. 
marinum and grown until saturated. Cultures were diluted to an OD600 of 0.05 in 50 mL of 
media and grown in 250 mL shake flasks. At 3 time points, with 3-hour intervals, throughout 
the working day, 1 mL samples were taken and the OD600 measured using a 
spectrophotometer (Ultrospec 2100 Pro; GE Healthcare).  
 
2.5 Heat-killing assay 
 
5 mL cultures of M. marinum were grown to an OD600 of 0.2 at 30 °C before a serial dilution 
of each culture from 10-1 to 10-6 was performed in 1.5 mL eppendorf tubes using 7H9 
supplemented with OADC and 0.05 % Tween-80 to give a final volume of 900 µl per tube. 
Tubes were placed at 30 °C, 100 RPM for 4 hours. An 8 µl sample from each tube was 
spotted onto a square 7H10 OADC antibiotic agar plate. Tubes were then placed in a heated 
water bath and samples taken at 30, 60, 120 and 180 minutes and spotted onto agar plates as 








2.6 Plasmid DNA extraction 
 
Plasmid containing strains were grown in LB supplemented with appropriate antibiotics (and 
0.2% arabinose for MGM100 strains) overnight at 37 °C, 180 RPM in a shaking incubator.  
Plasmid DNA was then extracted using either a QIAprep Spin Mini Kit (QIAGEN) or 
GeneJET Plasmid Miniprep Kit  (Thermo Scientific). Plasmid DNA was quantified using a 
nanodrop 2000.  
 
2.7 Heat shock transformation of E. coli 
 
E. coli DH5α cells were made competent according to the standard protocol: 
A 5 mL overnight culture of DH5α was pelleted by centrifugation (4000 RPM, 20 minutes, 4 
°C). Cells were resuspended in 10 mL of ice-cold 0.1 M CaCl2 and incubated on ice for 20 
minutes. Another centrifugation step (with the same settings as before) was performed and 
cells were resuspended in 5 mL of ice-cold 0.1 M CaCl2/15 % Glycerol (vol/vol) and 
separated in to 200 µl aliquots in sterile 1.5 mL eppendorf tubes. Cells were stored at -80 °C 
for future use. 
 
In a sterile eppendorf tube 2 µl of plasmid DNA (H2O used as a negative control) was added 
to 100 µl of competent cells, mixed gently by tapping the tube and then incubated on ice for 
30 minutes. Tubes were then heat-shocked at 42 °C for 60 seconds and immediately replaced 
on ice. After 3 minutes, 800 µl of LB was added to each tube and mixed by gently pipetting 
before incubation at 37 °C, 180 RPM for 1 hour. After incubation 100 µl of cells were 
pipetted onto an LB agar plate supplemented with 50 µg/ml Kanamycin and spread using 
sterile glass beads. Plates were incubated at 37 °C overnight. 
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2.8 Transformation of M. marinum  
 
M. marinum strains were grown in 100 mL of 7H9 supplemented with OADC, 0.05% Tween-
80 and appropriate antibiotic to mid-log phase. Cells were harvested by centrifugation at 5000 
rpm for 15 minutes. The supernatant was discarded before pelleted cells were resuspended in 
25 mL of ice-cold 10% (w/v) glycerol solution. The resuspended cells were centrifuged (5000 
rpm, 15 minutes). Two more centrifugation steps were performed under the same conditions 
with cells resuspended in 12.5 mL and then 7.5 mL of 10% glycerol solution. After the fourth 
centrifugation step the cell pellet was resuspended in 1 mL of 10% glycerol. Cells were then 
divided into 200 µl aliquots and stored at -20 °C. 
Cells were thawed on ice shortly before use. Up to 1 µg of plasmid DNA was added to the 
cells, mixed gently by pipetting and incubated on ice for 10 minutes. Samples were then 
transferred to 0.1 mm electroporation chambers and subjected to a pulse of 2.5 kV using an 
electroporator (Eppendorf Eporator). 1 mL of 7H9 (+ OADC & 0.05% Tween-80) was 
immediately added to the transformed cells. The sample was transferred to a sterile 1.5 mL 
eppendorf tube and grown at 30 °C for 24 hours. After incubation, 100 µl of cells were 
transferred to a 7H10 agar plate (+ OADC, appropriate antibiotics), and spread using glass 
beads before being incubated at 30 °C until colonies appeared. 
 
2.9 Preparation of glycerol stocks 
 
Cultures of bacteria were grown to late-log phase (overnight for E. coli and for 1 week for M. 
marinum). Cultures (1.5 mL) were centrifuged for 5 minutes at 14000 RPM to pellet cells. 
Cells were then resuspended in 1.2 mL of 15% (vol/vol) glycerol and 300 µl of the standard 
growth media of the bacteria (7H9 for M. marinum, LB for E. coli) and stored at -80 ºC. 
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2.10 RNA Extraction 
 
5 M GTC Solution:  
• 5 M guanidine thiocyanate 
• 0.5 % Sarkosyl 
• 25 mM tri-sodium citrate, pH7 
• 0.1 M β-mercaptoethanol 
• 0.5 % Tween-80 
 
A 150 mL culture of M. marinum (7H9 + OADC + 0.05 % Tween-80) was grown at 30 °C to 
mid-log phase.  A 10 mL sample of culture was taken and transferred to a sterile 50 mL 
Falcon tube to which 40 mL of 5 M GTC solution was added. The sample was mixed by 
inverting the tube 4-6 times. The remaining cultures were incubated at either 30 °C (normal 
conditions) or 45 °C (heat-shock conditions), with 10 mL samples taken at 10 minute, 30 
minute and 1 hour time points.  All samples were prepared as before with the addition of 40 
mL 5 M GTC solution. Samples were then centrifuged at 3000 RPM for 30 minutes to pellet 
the cells. The supernatant was discarded and pellets were resuspended in 1 mL of 4M GTC 
solution and transferred to a 1.5 mL eppendorf tube. Tubes were centrifuged for 1 minute at 
13000 RPM and the supernatant was discarded. Pellets were resuspended in 1.2 mL of TRI 
reagent (Sigma Aldrich) and transferred to a 2 mL screw-cap tube containing 0.1 mm ceramic 
beads (Lysing Matrix B, MP Bio).  Tubes were then placed in a reciprocal shaker (Ribolyser 
Homegeniser, Hybaid), which was run at 6.5 speed for 45 seconds. Tubes were then left at 
room temperature for 10 minutes before the addition of 200 µl of chloroform and then mixed 
by vortexing for 30 seconds. Samples were incubated at room temperature for 10 minutes 
before centrifugation at 13,000 RPM, 4 °C for 15 minutes. The newly formed upper phase of 
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each sample was transferred to a fresh eppendorf tube and 1 vol of chloroform was added 
before vortexing and incubation at room temperature for 10 minutes. Centrifugation (13,000 
RPM, 4 °C, 15 minutes) separated the samples into two phases. The upper phase to a new 
eppendorf and 0.8 vols of isopropanol was added. Samples were incubated at -20 °C 
overnight and then centrifuged (13,000 RPM, 4 °C, 15 minutes). Supernatant was discarded 
and the pellet was washed with 70% ethanol before re-pelleting (13,000 RPM, 4 °C, 15 
minutes) and air-dried to remove excess ethanol. Pellets were resuspended in 100 µl of 
nuclease-free water. RNA samples were subject to RNA clean-up using an RNeasy mini kit 
(QIAGEN). RNA was quantified using a UV-vis spectrophotometer (Nanodrop 2000, Thermo 
Scientific). 
 
2.11 cDNA synthesis 
 
cDNA was created from RNA samples using a Tetro cDNA Synthesis Kit (Bioline) according 
to manufacturers instructions. Random hexamers were used as the primers. RNA volume was 
adjusted for each sample to normalize the concentration across all reactions.  For DMSO 
gradient experiments volume of DEPC-treated water was adjusted to accommodate for any 








Incubation steps were performed in a thermal cycler (Mastercycler Pro-S, Eppendorf) using 
the following programme:  
 
Step Temperature (°C) Time (minutes) Cycles 
Annealing 25 10 1 
Reverse 
Transcription 




85 5 1 
Hold 4 ∞ n/a 
 
cDNA concentration was quantified using the dsDNA HS Assay Kit on a Qubit 2.0 













2.12 gDNA extraction 
 
GTE solution: 
• 50 mM glucose 
• 25 mM Tris-HCl, pH 8 
• 10 mM EDTA 
 
A culture of M. marinum was grown to mid-log phase. Cells (2 mL) were harvested by 
centrifugation (14,000 RPM, 5 minutes). Cell pellet was resuspended in 450 µl GTE + 50 µl 
lysozyme (10 mg/ml) and incubated at 37 °C overnight. After incubation 100 µl of 10 % SDS 
and 50 µl of proteinase K was added to the tubes. Samples were then incubated at 55 °C for 
30 minutes. NaCl (5M; 200 µl) was then added to each sample before the addition of 1 mL 
chloroform, vortexing and centrifugation at 8000 RPM for 6 minutes. The newly formed 
upper phase was transferred to a fresh eppendorf tube and 0.7 vol of isopropanol was added 
before incubation at room temperature for 10 minutes. Tubes were then spun at 8000 RPM for 
10 minutes and the supernatant was discarded. The pellet was washed with 70% ethanol and 
centrifuged at 8000 RPM for 10 minutes. Pellets were air dried at 65 °C for 15-20 minutes 
before resuspension in 100 µl of nuclease-free water. 
 
gDNA concentration was quantified using the dsDNA HS Assay Kit on a Qubit 2.0 






2.13 Polymerase Chain Reaction (PCR) amplification of DNA 
PCR was performed using either cDNA or gDNA. Initial primer annealing temperature 
optimization was performed using Phusion polymerase (NEB), combined with the provided 
5x High GC Buffer and 3% DMSO. Reactions were prepared in 1.5 mL eppendorf tubes and 














































PCR products were run on a 2% agarose gel stained with Midori green. 






2.14 Quantitative Real-Time PCR (qRT-PCR) 
 
Primer design: 
Primers for qRT-PCR are integral to the success of the experiment. Non-specific binding of 
primers will amplify unwanted regions of DNA giving a fluorescent signal non-representative 
of GOI amplification. Dimerisation and secondary structures of primers will also bind SYBR 
green and therefore increase fluorescence.  
Following the primer design protocol outlined in (Thornton & Basu, 2010), Primer3 primer 
design software (available at: http://frodo.wi.mit.edu/primer3/; Rozen et al, 2000) was used to 
identify the best primer pair for each gene sequence (obtained through MarinoList at 
mycobrowser (available at: http://mycobrowser.epfl.ch/), Kapopolulou, Lew & Cole, 2011).  
Obtained primer pairs were then inputted into Beacon Designer™ Free Edition (available at: 
http://free.premierbiosoft.com) to check for potential primer self-dimerisation, cross-
dimerisation and secondary structure.  Any primers that formed any structure with ∆G values 
<-3.5 kcal/mol were rejected. To check for amplicon secondary structure the program, mFold 
(available at: http://www.idtdna.com?Scitools/Applications/mFold; ), was used. Due to the 
relatively high GC content of the M. marinum genome and the short length of cpn10 gene, 
amplicon secondary structures were unavoidable without compromising on other, more 
essential primer parameters. Finally nucleotide BLAST (available at: 
www.ncbi.nlm.nih.gov/BLAST; Lobo, 2008) searches were performed against the M. marinum 
genome to check primer specificity. Primers with non-specific priming targets were discarded 
and redesigned.  
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Primers for qPCR were designed by following the protocol described by Thornton and Basu, 
2010, and were synthesized by Illumina. Reaction master mix for each primer pair were 
prepared on ice in a sterile eppendorf tube, with the following composition: 
 
Total volume per well = 20 µl 
• 10 µl Brilliant II SYBR Master Mix (Agilent Technologies) 
• 1 µl forward primer 
• 1 µl reverse primer 
• 1 µl DMSO 
• x amount of DNA 
Volume adjusted to 20 µl using nuclease-free H2O 
 
Master mix was aliquoted into wells on a 96-well plate, non-skirted (Agilent Technologies) 
and kept at 4 °C using a PCR-cooler (Eppendorf). DNA was then added to each well. Each 
reaction was performed in duplicate with no template controls (NTCs) for each primer pair. 
The 96-well plate was sealed using optical caps (8x strip; Agilent Technologies). Plates were 
centrifuged (Sigma 4-15C, QIAGEN) at 4000 RPM for 3 mins. Reactions were performed in 










































































2.15 Restriction digests 
 
Restriction digests were performed at both 20 µl and 50 µl reaction volumes. All restriction 
enzymes used were NEB. Reactions were performed according to manufacturer's protocol.  
Component 20 µl reaction 50 µl reaction 
10x Buffer 2 µl 5 µl 
Restriction Enzyme 1 µl 2 µl 
DNA ~400 ng ~1 µg 
dH2O To 20 µl To 50 µl 
 
 
2.16 Gel electrophoresis 
 
Depending on the expected size of the PCR product either 1% or 2% agarose gels were run: 
For products as a result of qPCR primers, 2% gels were achieved by dissolving 2 g of agarose 
in 100 ml of 1x TAE buffer and heating until dissolved. Midori green direct stain (5 µl per 
100 ml of agarose; Nippon Genetics Europe) was used for Phusion polymerase based 
reactions. For SYBR green based reactions no stain was added to the gel. DNA samples were 
prepared by mixing 3 µl 5x DNA loading buffer blue (Bioline) with 5 µl nuclease-free H2O 
and 7 µl of PCR product. Hyperladder IV (100 bp; Bioline) was used as a marker.  
 
For restriction digest products 1% gels were made by dissolving 1 g of agarose in 100 ml of 
1x TAE buffer and stained with Midori green.  
Gels were run at 120 V, 500 mA for 40 mins (small gels) and 1 hour (large gels).  
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2.17 Gel-Purification of DNA 
 
Gels were visualized using a near-UV LED viewer (Helixx UltraSlim LED viewer; Helixx). 
Bands of interest were excised using a sterile scalpel and transferred to a pre-weighed 
eppendorf tube. Tubes were re-weighed and the weight of the gel slice determined. DNA was 
then purified using a QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
protocol.  Purified DNA was quantified using a nandrop 2000. 
 
2.17 Lipid extraction 
 
A single colony of M. marinum was used to inoculate 5 mL of 7H9 media supplemented with 
OADC and antibiotic and grown for 7 days or until late-log phase was reached. Smaller 
cultures were then used to inoculate 200 mL of 7H9 media supplemented with OADC and 
antibiotic in a 1 L shake flask. Large cultures were grown at 30 °C , 100 RPM until saturated. 
Culture (50 mL) was transferred to a 50 mL falcon tube and cells were harvested by 
centrifugation at 4000 RPM for 30 minutes. Supernatant was discarded and more culture was 
added to the same tube to 50 mL before re-harvesting. This was repeated until all cells had 
been harvested. Cells were resuspended in 10 mL 1x Phosphate Buffered Saline (PBS), and 
transferred to a 15 mL borosilicate screw neck, rounded base tube (125 mm x 16 mm; Pyrex, 
Appleton Woods). Tubes were spun at 3000 RPM for 15 minutes before discarding 
supernatant and drying pellets for 1.5 hours in a heating block set to 50 °C under a stream of 
nitrogen gas. 50-100 mg of dried biomass was transferred to a fresh borosilicate tube (referred 
to onwards as tube A) and resuspended in a solution of Methanol and 0.3% NaCl mixed in the 
ratio 10:1 followed by 1 ml of petroleum ether (60-80 C). Tubes were mixed on a rotor and 
placed in an ultrasonic cleaner (need model info) to ensure complete resuspension. Tubes 
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were then centrifuged at 3000 RPM for 15 mins and the newly formed upper layer transferred 
to a pre-weighed borosilicate tube (referred to onwards as tube B). 1 mL of petroleum ether 
(60-80 C) was added to the remaining lower layer of Tube A, mixed on a rotator for 15 
minutes and then centrifuged for 5 mins at 3000 RPM. The upper layer was transferred to 
tube B, which was then dried on a heating block at 50 °C under nitrogen gas. The weight of 
tube B was recorded and the mass of non-polar lipid weight was calculated by subtracting the 
empty weight of tube B previously recorded.  The dried non-polar lipids were resuspended in 
200 µl of 2:1 chloroform:methanol 
 
2.3 mL of a 9:10:3 chloroform:methanol:0.3% NaCl solution was added to the remaining 
contents of tube A, which was then mixed on a rotator for 60 minutes and then centrifuged for 
5 minutes at 3500 RPM. The supernatant was then transferred to another pre-weighed 
borosilicate tube (named tube C). A 5:10:4 solution of chloroform:methanol:0.3% NaCl (750 
µl) was added to tube A, mixed on a rotator for 30 minutes and centrifuged for 3 minutes at 
3500 RPM. The supernatant from tube A was then transferred to tube C. The previous 5:10:4 
chloroform:methanol:0.3% NaCl step was repeated again and the supernatant added to tube C. 
To tube C 2.6 mL of a 1:1 chloroform:0.3% NaCl solution was added, mixed on a rotator and 
centrifuged for 5 mins at 3500 RPM. The bottom phase consisting of the purified polar lipids 
was transferred to a clean pre-weighed borosilicate tube (tube D) and dried at 50 °C under 
nitrogen gas before resuspending dried material in 200 µl of a 2:1 chloroform:methanol 
solution. Tube D was weighed and mass of polar lipids calculated by subtracting the empty 





2.19 Two-Dimensional Thin Layer Chromatography (2D-TLC) 
 
Aluminium TLC plates (20x20 cm; aluminium oxide matrix; Sigma Aldrich) were cut into 
6x6 cm size squares (36 cm2). A small pencil mark was placed 1 cm from the horizontal and 
vertical edges in one corner of the plate. Plates were labeled using a paper along the edge of 
the plate below the pencil mark. Four plates were required per sample of non-polar lipids and 
2 plates for each sample of polar lipid.Six solvent systems were run in total, 4 for non-polar 
and 2 for polar lipids. 
Lipid type System Direction Constituents 
Non-polar 
A 
1 Petroleum ether:ethyl acetate (98:2) 
2 Petroleum ether:acetone (98:2) 
B 
1 Petroleum ether:acetone (92:8) 
2 Toluene:acetone (95:5) 
C 
1 Chloroform:methanol (96:4) 




1 Chloroform:methanol:water (100:14:0.8) 
2 Chloroform:acetone:methanol:water(50:60:2.5:3) 
Polar E 
1 Chloroform:methanol:water (60:30:6) 
2 Chloroform:acetic acid:methanol:water(40:25:3:6) 
 
Purified lipids were normalized by diluting to a concentration of 10 µg/µl using 2:1 
chloroform:methanol. A 10 µl sample of lipid was drawn into a pipette and spotted onto the 
pencil mark on the plate by capillary action, with the spot diameter not exceeding ~5 mm. 
Spots were allowed to dry before the sample was re-spotted and this was repeated until all 10 
µl of sample was spotted on the plate. 
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Solvent solutions were freshly made before use. Solvent solution (50 mL) was placed in a 
glass TLC tank, which was then closed with a lid and allowed to equilibrate for 15 mins. 
After 15 mins the lid was opened slightly and the TLC plates placed in the tank with ~0.5 cm 
of the plate submerged in the solution. The tank lid was replaced and the TLC plates removed 
once the solvent front reached the top of the plate. At this point the plates were removed and 
left to dry at room temperature. The solution was discarded in the appropriate manner before 
the tank was washed with acetone and dried. Certain solvent systems required more than one 
“direction 1” or “direction 2” run using the same solution. (see Table for details). The next 
solvent solution “direction 2” was placed into the tank and this was again allowed to 
equilibrate with the lid on. Once dried the plates were then placed in the tank, rotated about 































This method applied to all solvent systems with the exception of System E, which required 
the baking of the TLC plates for 15 minutes at ~90 °C prior to running the direction 1.  
 
TLC plates were stained with (need to find out) and developed by heating with a heat gun.  
 
2.20 Biofilm formation assay (from Rao, 2010) 
 
Biofilm base media: 
• 100 mM Monopotassium Phosphate KH2PO4 
• 15 mM (NH4)2SO4, pH 7.0 (adjusted using KOH) 
• 0.5 mg Iron Sulphate Heptahydrate FeSO4.7H2O 
• 5 g Casamino acid 
Biofilm media: 
• 94 ml Biofilm base media 
• 5 ml 40% glucose 
• 1 ml 0.1 M Calcium Chloride CaCl2 
• 100 µl 1 M Magnesium Sulphate MgSO4 
 
 10 ml of Biofilm media was aliquoted into a small petri dish (60x15 mm). 10 µl of a mid-log 
phase culture of M. marinum or M. smegmatis was added to the centre of the petri dish and 






2.21 Pellicle formation assay 
 
To sterile test tubes, 5 mL of 7H9 media with OADC (no Tween-80) was aliquoted. Samples 
(1 mL) of mid-log phase cultures of M. marinum and M. smegmatis were transferred to 
autoclaved eppendorf tubes and centrifuged for 2 minutes at 1000 RPM to pellet clumped 
cells. Supernatant (10 µl) was taken from each sample and pipetted into their respective test 
tube. Tubes were incubated at 30 °C for 7 days, after which they were photographed and 
length of pellicle formation was measured in mm using a ruler.  
 
2.22 Investigation of cell clumping characteristics 
 
Centrifugation, needle-pass and further centrifugation test: 
Cultures of M. marinum wild type and ∆cpn60.1 were grown to either early or late log phase. 
Samples (1.5 mL) were taken from each culture and transferred to a sterile eppendorf tube. 
Tubes were centrifuged for 2 minutes at 1000 RPM to pellet cell clumps. Supernatant (100 µl) 
was used to establish a serial dilution from 10-1 to 10-4 of which 100 µl were plated on 7H10 
agar and spread using sterile glass beads. The OD600 of the remaining supernatant was 
measured for each sample. Using a 23G needle and a sterile 5 mL syringe, 5 mL of the 
original culture was passed in and out of the syringe 3 times. Another serial dilution using the 
same range as before was established and plated on 7H10. The OD600 of the syringed cells 
was recorded. Samples of the syringed cells (1.5 mL) were taken and transferred to eppendorf 
tubes. Tubes were centrifuged for 2 mins at 1000 RPM and 100 µl of supernatant taken to 
establish a serial dilution, which was then plated as previously described. The OD600 of the 




Two 5 mL cultures of wild-type and ∆cpn60.1 M. marinum were grown to mid-log phase. 
Using a 23G needle and 5 mL syringe the samples were passed in and out of the syringe 4 
times. The OD600 was taken after each pass and 100 µl of cells were used to create a serial 
dilution to 10-6 from each pass. Three samples of each strain (10-4 to 10-6) were plated on 




Two 5 mL cultures of wild-type and ∆cpn60.1 M. marinum were grown to mid-log phase. An 
initial 100 µl of each culture was taken and placed in a sterile eppendorf tube. Using a 23G 
needle and 5 mL syringe the remaining cultures were passed through a syringe needle. 
Samples (100 µl) were taken in between each needle pass. Each sample was used to create a 
serial dilution to 10-6 from each pass. Samples (20 µl) were pipetted into the hemocytometer 
under the cover slip and observed using the x40 objective lense of a microscope (Alphaphot 
YS2-T; Nikon) using the phase contrast setting Ph4. Total cells found in each corner quadrant 












3.1 Growth rates of wild-type and ∆cpn60.1 M. marinum  
 
The first experiment performed was to establish growth curves for ∆cpn60.1 strains of and 
wild type M. marinum. This was required to ensure that difference in growth rate didn’t 
impact any future growth-based experiments. Two isolates of each strain were used; wild type 
1 (wt1), wild type 2 (wt2), ∆cpn60.1 1#1 and ∆cpn60.1 2#1. Both of these strains had 
previously been transformed with the plasmid pMSP-dsRed (kanaR) for fluorescent detection 
in zebrafish (Danio rerario) embryo infection models. All strains were streaked on to 7H10 
agar from frozen -80 °C glycerol stocks and selected for using the appropriate antibiotics. 
Single-colony liquid cultures were then grown and used to inoculate a larger liquid culture to 
a starting OD600 of 0.05. The effect of diluting M. marinum on OD600 was not linear -values 
calculated using the equation c1v1=c2v2 were incorrect by a factor of 4. To achieve the correct 
dilution, calculated values were divided by 4 and this volume of cell culture was used to 
inoculate. This effect was due to the high frequency of cell clumping of M. marinum at higher 
OD600 values (discussed later). Readings were taken three times a day with ~3 hour intervals. 
 
Fig.3. compares the growth rates of all M. marinum strains used. No significantly different 
rate in growth can be observed between the strains meaning there is no growth bias that would 
affect growth-based experiments. Reproducibility of this experiment was an issue. The rates 
of growth appeared to vary between repeats, with the wild-type cells entering log-phase 






Fig. 3.1 Growth rates of M. marinum wild type and ∆cpn60.1 strains. (Top) Run 1, issues 
were had achieving the correct starting OD600 nm, therefore this run started from an OD600 nm of 
~0.1 for each strain. (Below) Run 2, all strains were diluted to a starting OD600 nm of ~0.05. 































wild type 2 
wild type 1 
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3.2 Heat-killing experiments  
 
Previous experiments have documented the effect of cpn60.1 loss on temperature sensitivity. 
∆cpn60.1 mutants of Mycobacterium tuberculosis were shown to have an increased sensitivity 
at 55 °C, with this temperature killing the knockout faster than the wild-type strain (Hu et al., 
2008).  In M. smegmatis there is a >100-fold up-regulation of cpn60.1 expression in response 
to heat shock at 42 °C (Rao and Lund, 2010).  To investigate the role of cpn60.1 during the 
heat shock response, both wild-type and ∆cpn60.1 M. marinum were exposed to three 
different temperatures above that of their optimal growth temperature of 30 °C; 37 °C, 45 °C 
and 50 °C.  Samples were taken at 30 minutes, 1 hour, 2 hours, 3 hours and grown on 7H10 
media for one week at 30 °C.  
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Fig.3.2 Effect of heat shock on the survival of M. marinum wild type and ∆cpn60.1 strains. 
On each plate top row = wild type 1, second row from top = wild type 2, third row = 











Fig.3.2 shows the survival of M. marinum strains at different heat shock temperatures. At 37 
°C no change is observed between wild type and ∆cpn60.1 strains after 3 hours. At 45 °C the 
∆cpn60.1 strains show a clear survival advantage against heat shock. After 30 minutes at 45 
°C there is little difference between the strains. In the 1-hour samples we start to see an 
increase in the killing of the wild type strains and after 3 hours nearly all wild type cells have 
been killed whilst the ∆cpn60.1 strains have survived.  This trend is repeated in the results 
from the 50 °C exposure experiment except over a shorter timeframe with all strains 
completely killed after 2 hours.  
 
3.3 Quantitive Real-Time PCR analysis of cpn gene expression 
 
Quantitative real-time PCR is a method of measuring the level of transcription of genes in a 
given sample. It requires a reverse transcription step to convert RNA isolated from a sample 
to complementary DNA (cDNA).  Like standard PCR DNA is then amplified using gene-
specific primers and Taq polymerase. However, in qPCR the use of certain fluorescent dyes 
allows the reaction to be quantified in real-time. For this set of experiments SBYR green dye 
was used which emits a fluorescent signal in the presence of double-stranded DNA. As target 
DNA is amplified the fluorescence signal increases. Therefore by measuring fluorescence the 
relative amount of cDNA of the gene of interest (GOI) can be determined, and therefore it’s 
level of transcription.  
Following on from the heat-killing experiments we wanted to identify how the transcription 
of all three cpn genes (cpn10, cpn60.1 and cpn60.2) changes in response to heat shock and 
their difference in expression between wild-type and ∆cpn60.1 mutant. Expression of a 
housekeeping gene, in this experiment gap (MMAR_2239, Glyceraldehyde 3-phosphate 
dehydrogenase), needs to be measured in every sample to normalize the data between each.  
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3.3.1 Optimising qRT-PCR conditions  
 
PCR was performed to check the validity of designed primers. Due to the unavoidable 
amplicon secondary structure, reaction conditions were varied to determine the optimal setup. 
The first experiment performed involved varying the primer annealing temperature from 55 
°C to 75 °C.  This experiment was performed using Phusion polymerase and included 3% 
DMSO. Fig. 3.3 shows the results of the annealing temperature variation experiment. 
Products were run on 1% agarose gels (cpn10, cpn60.1 and cpn60.2) or 2% agarose (gap).   
 
 
Fig.3.3 PCR products of qPCR primer amplification, varying annealing temp. A gradient of 
annealing temperatures of 55 °C to 75 °C was used. Expected product sizes: for cpn10 – 87 




Primers for cpn10 annealed at temperatures from 54.8 °C to 66 °C, but not above. Annealing 
temperatures from 54.8 °C to 68.6 °C were sufficient to amplify cpn60.1. However, both 
cpn60.2 and gap suffered from non-specific amplification at certain annealing temperatures. 
At 54.8 °C and between 60.7 and 63.3 °C primers for cpn60.2 show a second band indicating 
amplification of a secondary product. Likewise, at 56.5 and 58.3 °C a second product is seen 
in the gap primer-amplified samples. An annealing temperature of 56 °C was chosen for 
future experiments, avoiding the production of secondary products produced by cpn60.2 and 
gap primers. 
 
3.3.2 Testing qRT-PCR primer efficiency 
 
Genomic DNA (gDNA) was purified from a culture of M. marinum wild type 2. A serial 
dilution from 1x to 10-10 of gDNA was established and a run of qPCR performed to create 
standard curves of each primer pair.  
 
%
Fig.3.4 Fluorescence signal output of qPCR reaction on serial dilution of gDNA to test 
efficiency of each primer pair 
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Fig. 3.4 shows that the efficiencies of all primer pairs were very similar. DNA concentrations 
that fall within the linear portion of the standard curve are deemed ideal for further 
experiments, in this case a fluorescence value (Ct) in the range of ~15 to ~27. QRT-PCR 
products were run on 2% agarose (Fig. 3.5).  
 
Fig. 3.5 (top) qPCR products from cpn60.1 and gap primer pairs run on 2% agarose. (Bottom) 
the effect of varying DMSO concentration on cpn60.1 and gap PCR product formation 
 
Products formed from the cpn60.1 primers (Fig.3.5, top) showed some smearing indicative of 
the presence of secondary structure in the amplicon. A non-specific product was formed in the 
amplification using gap primers, but not at all gDNA concentrations. The use of DMSO to 
reduce secondary structure in high GC content DNA templates has been well documented 
(Jensen, 2010; Mammedov, 2008). In the original primer optimization experiments DMSO 
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had been included in the reaction mixture at 3%. However, DMSO was not added to the 
qPCR reaction. To investigate whether addition of DMSO alleviated the smearing and non-
specific amplification observed in cpn60.1 and gap qPCR products, the PCR was repeated 
using a gradient of DMSO from 0% to 10% in 2% increments.  Fig. 3.5 (bottom) shows that 
DMSO appeared to alleviate non-specific amplification in gap and no smearing is observed in 
the cpn60.1 products. 
 
3.3.3 RNA isolation from heat-shocked M. marinum strains 
 
The results of the initial heat-shock experiments indicated that ∆cpn60.1 mutants of M. 
marinum appeared to have a higher rate of survival under heat-shock conditions. At 50 °C the 
cells were killed between the 1 and 2 hour mark, but at 45 °C the wild type survived until the 
3 hour mark, therefore 45 °C was chosen as the working temperature to investigate the change 
of expression of the cpn genes under heat-shock. Single cultures of wild type 1 and ∆cpn60.1 
1#1 were grown to mid-log phase and split into two 50 mL cultures, each. One culture of each 
strain was kept at 30 °C to act as a control whilst the other was moved to 45 °C. Samples of 
the 30 °C cultures were taken after 1 hour to compare to the 0 minute sample to ensure there 
is no change in gene expression at the control temperature. Samples were taken from the 45 
°C cultures at 0, 10, 30 and 60 minutes after exposure to heat-shock. GTC solution was 
immediately added to each sample after sampling. The main component of GTC, guanidine 
thiocyanate is a potent inhibitor of RNase when present at high concentrations, in this case 4 
molar. This acts to prevent the degradation of the mRNA, providing the transcriptome of the 
culture at that specific point in time.  RNA was purified (see methods) and cDNA synthesized 
adjusting RNA volume to normalize the concentration of starting template.  
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3.3.4 qRT-PCR of cDNA samples 
 
A serial dilution of each cDNA sample was made ranging from 10-1 to 10-7. As the efficiency 
of each primer pair had previously been established as roughly equal, preliminary 
experiments were performed with only the primer pair for gap amplification. Serial dilutions 
of cDNA were assayed to create a standard curve. Initially concentrations ranging from 1x to 
10-7 were run, but were found to be too low, with most concentrations not lying within the 
linear portion of the curve, where Ct < ~27. A further run with 3 µl of each cDNA sample per 
well was performed, and although the Ct values obtained were within the acceptable range 
(Fig. 3.6), but the remaining volume of cDNA stock was too low for replicates of each primer 











3.3.5 Optimising cDNA synthesis 
 
Due to the low concentration of cDNA, the reverse transcriptase (RT) protocol was revisited. 
By increasing the length of the reverse transcription step from 30 minutes to 60 minutes it was 
hoped that amount of product would be increased. The temperature of the RT step was also 
increased from 45 °C to 47 °C to help decrease any RNA template secondary structures. 
Resulting cDNA was diluted to 10-1 concentration and quanitified using a Qubit dsDNA high-
specificity assay kit and compared to the cDNA previously created, which acted as a control. 
Fig. 3.7 shows that cDNA created using the altered protocol was much lower than the cDNA 
created using the standard protocol.  
 
 
Fig.3.7% The! effect! of! increasing! the! Reverse! Transcriptase! step! duration! and!
temperature!on!cDNA!yield.!From!left!to!right!M.#marinum#wildRtype!1!samples:!after 60 
minutes at 30 °C (wt 1 30-60), after 10 minutes at 45 °C (wt1 45-10), after 30 minutes at 45 
°C (wt1 45-30), after 60 minutes at 45 °C (wt1 45-60), ∆cpn60.1 1#1; at t= 0 minutes (∆1#1 
0), after 60 minutes at 30 °C (∆1#1 30-60), after 10 minutes at 45 °C (∆1#1 45-10), after 30 
minutes at 45 °C (∆1#1 45-30), after 60 minutes at 45 °C (∆1#1 45-60).!
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Next the effect of adding DMSO and varying its concentration on cDNA yield was studied. 
RNA isolated from ∆cpn60.1 1#1 from 45 °C after 60 minutes was used and the reaction was 
run according to standard thermal profile settings. DMSO was varied at 3%, 6% and 9% (with 
a 0% control), DMSO concentration above 10% was avoided as at this concentration and 
above it starts to lower the annealing temperature of the reaction and inhibits Taq polymerase 
activity by 47% (Sun, 1993). Unlike before, cDNA was quanitified using the UV-vis 
spectrophotometer. Although not an entirely accurate measure due to the constituents of the 
cDNA synthesis reaction, the values are relative to one another allowing a simple comparison 




Fig. 3.8 The effect of increasing DMSO concentration on cDNA yield. Concentration of 
DMSO was varied in the reaction mixture of the cDNA protocol. Volume of ddH2O was 
adjusted to maintain a constant final reaction volume. 
 
The results (Fig.3.8) appear to indicate that varying DMSO has no real effect on the yield of 
cDNA achieved.  
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3.3.6 qRT-PCR of cDNA samples (cont.) 
 
Due to time constraints it was decided that qRT-PCR would be performed using the cDNA 
synthesized initially using the standard cDNA synthesis protocol. Concentrations of cDNA 
used were normalized to the fluorescence of the weakest sample (wild type 1 45°C, 60 
minutes) at 1x concentration by identifying the dilutions with Ct values closest to 29 (using 
the standard curves generated previously). All samples were run in duplicate for each primer 
pair along with duplicate no template controls.  
Fold change of induction of genes were calculated using the ∆∆ct method: 
 
Fold change = 2-∆∆ct 
where ∆∆ct =  [(Ct of GOI – Ct internal control)standard condition –  
(Ct of GOI – Ct internal control) variable condition] 
(taken from Schmittgen & Livak, 2008) 
 
Fig. 3.9 qRT-PCR based detection of the expression of cpn genes in M. marinum ∆cpn60.1 
strain with respect to levels of cpn expression observed in M. marinum wild type strain, both 


















Expression of cpn genes in M. marinum 
∆cpn60.1 
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Overall poor quality of cDNA had a negative impact on the quality of the results achieved, 
with fluorescence intensity values of the individual reactions rarely falling within the 
acceptable 15-27 Ct range.   
 
Fig. 3.9. shows the relative expression of the cpn genes observed in the ∆cpn60.1 strain of M. 
marinum under normal growth conditions. In consensus with previous findings in M. 
smegmatis (Rao & Lund, 2010), cpn10 is the most highly expressed of the cpn genes followed 
by cpn60.2. Expression of cpn60.1 was also detected, at levels higher than that of those found 
in wild-type strain samples, bringing again into question the validity of these results. 
 
 
Fig. 3.10 qRT-PCR based detection of the change in expression of the cpn genes during heat 
shock (45 °C) in wild type M. marinum. Values have been normalized to the expression of 





























Fig. 3.10 shows that in wild type M. marinum, fold induction of the expression of cpn60.1 and 
cpn60.2 increases by roughly 2 fold after 10 minutes after heat-shock (45 °C), with a 2.5-fold 
induction observed in cpn10 expression. After 30 minutes, fold induction of genes drops to 
less than a 1 fold increase, with cpn60.2 showing highest fold change of expression. After 60 




Fig.3.11 (Replicate 1 of 2) QRT-PCR based detection of the change in expression of the cpn 
genes during heat shock (45 °C) in ∆cpn60.1 M. marinum with respect to a 0 minute time 

































Fig. 3.12 (Replicate 2 of 2) qRT-PCR based detection of the change in expression of the cpn 
genes during heat shock (45 °C) in ∆cpn60.1 M. marinum with respect to the expression of 
the same genes under standard conditions. Values have been normalized to the expression of 
control gene gap. All values are derived from the mean results of technical duplicates. 
 
Fig. 3.11 shows the results obtained from the first replicate of the qRT-PCR investigation into 
the expression of the cpn genes in the mutant M. marinum ∆cpn60.1 strain under heat-shock 
at 45 °C. A massive increase in the fold induction of cpn60.2 is observed. Whilst this was a 
possibility hypothesized in response to the finding that heat-shock resistance is conferred by 
cpn60.1 loss, this level of induction was surprising. Repetition of this experiment was the next 
task performed. New cDNA samples were synthesized from fresh biological replicate 
cultures. The values displayed in Fig. 3.12 are the result of technical duplicates at the qRT-
PCR stage. Quality of cDNA obtained from this repeat was much higher, and this was 
































more valid than that shown in Fig. 3.11. Displaying a similar pattern of induction to wild type 
M. marinum, the fold change induction of expression of cpn10 and cpn60.2 is both increased 
after 10 minutes under heat-shock condition. This then decreases after 30 minutes, and again 
after 60 minutes at 45 °C. Low levels of expression of cpn60.1 were detected but this does not 
appear to be significant.  
 
3.4 Lipid profiling of wild type and ∆cpn60.1 M. marinum strains 
 
Previous experiments have identified key differences between the lipid profiles of wild type 
and ∆cpn60.1 mutants of M. smegmatis and M. bovis BCG. In M. bovis BCG ∆cpn60-1 
mutants, Pthiocerol dimycocerosates are absent (Wang, 2011) and in M. smegmatis GroEL1 
(cpn60.1) is required for the induction of C56-C68 fatty acids during biofilm formation (Ojha et 
al, 2005).  
 
Lipids were extracted from both wild type and ∆cpn60.1 M. marinum and the equivalent 
strains of M. smegmatis. 2D-TLCs were then performed of all samples using solvent sytems 
A-E (described in Minnikin et al, 1985) in order to separate out the multiple different classes 
of lipids found in Mycobacteria. The resulting lipid patterns formed on each plate where then 








Fig.% 3.13% 2DRTLCs! of!M.# marinum! wild! type! and! ∆cpn60.1# apolar# lipids.% (A)! solvent!
system! A,! (B)! solvent! system! B,! (C)! solvent! system! C,! (D),! solvent! system! D! (solvent!






Fig.% 3.14%2DRTLCs!of!M.#marinum!wild! type!and!∆cpn60.1#polar# lipids! separated!using!




Fig. 3.13 shows the results of apolar lipid separation using solvent systems A to D. In the 
TLC plates from both systems B and C there appears to be two differences observed in the 
∆cpn60.1 mutant compared to the wild type (Fig.3.13; indicated by arrows). Both system B 
and C resolve the same lipid class, the free fatty acids.  
 
The resulting TLC plates from samples run using solvent system E unsatisfactory (see 
supplementary data, S1) and due to time constrains could not be repeated. Even still, no 
visible difference was seen (although the validity of this statement is dependent on a repeat of 
the experiment). No obvious differences were observed in the polar lipids between wild type 








3.5 Generation of complemented strains of M. marinum ∆cpn60.1 
 
To determine whether the phenotype observed in the lipid profiles of M. marinum ∆cpn60.1 
was as a result of cpn60.1 loss or another unknown factor, complemented strains were 
generated.  
 
E. coli DH5α cells were transformed with each of the following plasmids;  
• pMSGroEL1, expressing GroEL1 (cpn60.1) from M. smegmatis 
• pMSGroEL2, expressing GroEL2 (cpn60.2) from M. smegmatis 
• pMS10.cpn60.2, a different plasmid expressing M. smegmatis cpn60.2 
• pMS10.cpn60.3, expressing M. smegmatis cpn60.3 
• pMS10. groEL, expressing E. coli GroEL 
All of these genes are in an operon with M. smegmatis cpn10 under the control of the Hsp60 
promoter from M. bovis BCG with KanR as a selectable marker. 
Plasmids were purified and sequenced against the qPCR primer MM_cpn10_F to determine 
the sequence downstream of cpn10 and confirm the identity of the plasmids. All plasmids 
were correct with the exception of pMSGroEL2, which was found to contain cpn60.1, most 
likely as a result of mislabeling of the eppendorf tube. 
Due to these plasmids containing a Kanamycin resistance gene the previously used ∆cpn60.1 
strains already transformed with KanR pMSP-dsRed meant that selection of complemented 
transformants could not be achieved using Kanamycin. Therefore, the ∆cpn60.1 mutant strain 
not transformed with pMSP-dsRed was used for these transformations.  
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Plasmids were initially eluted from the spin columns (as part of Qiagen kit) using the elution 
buffer provided, and thus were not de-salted.  Therefore, the first attempt at transformation 
used only 2 µl of plasmid DNA was used in each reaction. The protocol used was based on 
that found in Rao & Lund, 2010 for the transformation of M. smegmatis, using 400 µl of 
competent cells and an electroporation voltage of 1.8 kV. However, after 1-week incubation 
on solid media no distinct colonies had formed. Cultures of recombinant E. coli DH5α strains 
were grown and Plasmid DNA was again purified but instead of elution buffer, nuclease-free 
water was used for elution. Electroporation was performed according to the M. marinum-
specific protocol from El-Etr et al., 2004 (200 µl competent cells, 2.5 kV). Ahigh 
transformation efficiency was observed across all plates, with the exception of the 
pMScpn10.cpn60.3 strain, which only formed 1 colony. Glycerol stocks were created of each 
new strain and stored at -80 °C. 
 
3.5.1. Generation of a plasmid vector for the expression of M. marinum cpn60.1  
 
To act as a positive control in the complementation experiments - work was started to achieve 
a plasmid to express cpn60.1 from M. marinum. A strain of MGM100 containing the plasmid 
pTrcESmmcpn60.1 was grown and the plasmid purified. The exact details on the 
development of the pTrcESmmcpn60.1 were not clear. However, Rao (2010) had used 
pTrcES-X plasmids in the creation of the pMS10-X plasmids, where X refers to M. 
smegmatis cpn60.2, cpn60.3 or E. coli groEL genes. Generation of these plasmids is detailed 
in Rao (2010). All of the pTrcES-X plasmids contained at least one HindIII site flanking the 
cpn or groEL genes. Therefore digestion of pTrcESmmcpn60.1 with HindIII was performed 
but analysis of the product formed by gel electrophoresis revealed only 1 band of around 6 kb 
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in size, suggesting that only partial digest had been achieved. Due to time constraints this 
portion of the study was not followed up. 
3.5.2. Generation of a cpn10-expressing control plasmid for complementation 
 
All of the cpn60 genes available in the complementation plasmids are co-expressed with 
cpn10, efforts were made to develop a control plasmid containing only the cpn10 gene. The 
plasmid pMS10.cpn60.2 contains cpn60.2 flanked by HindIII restriction sites (Rao, 2010).  
Digestion was performed with HindIII and the product run on a 1% agarose gel. Two bands 
were observed when visualized using near-UV, the larger of which was excised and purified. 
The large DNA fragment, thought to be representative of pMS10.cpn60.2 with cpn60.2 
removed was left at room temperature to re-circularize.  Purification yield was low so 
sequencing couldn’t be performed to confirm identity. Instead, the plasmid was re-
transformed into E. coli DH5α and grown in presence of arabinose and kanamycin. However, 
after 24 hours no colonies were formed.  
 
3.6 2D-TLC analysis of lipid content of complemented M. marinum ∆cpn60.1 strains 
 
Large cultures (200 mL) of complemented strains were established and grown until saturated. 
Lipids were purified from pelleted cells according to the protocol described in section 2.17. 
Due to time constraints only solvent systems B and C (see section 2.18) were repeated using 
these complemented strains.  
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Fig.3.15. 2D-TLC separation of lipids using system B (see section 2.18). (Top left) wild-type 
M. marinum, (top right) ∆cpn60.1 M. marinum, (centre left) ∆cpn60.1 + M. smegmatis 
cpn60.1, (centre right) ∆cpn60.1 + M. smegmatis cpn60.2, (bottom left) ∆cpn60.1 + M. 
smegmatis cpn60.3, (bottom right) ∆cpn60.1 + E. coli groEL. Plates were developed using 





Fig.3.15 shows the results of the 2D-TLCs of M. marinum ∆cpn60.1 strain complemented 
with the different plasmids, run using system B. Separation of the lipids wasn’t as effective as 
seen in the previous experiment. Due to time constraints this experiment couldn’t be repeated. 
It appears that M. smegmatis Cpn60.1, Cpn60.2, Cpn60.3 and E. coli GroEL all restored the 
phenotype of the wild type M. marinum strain as no intense spot is observed (beneath spot 
marked with X in Fig.3.15). However, without repetition of this experiment and the previous 
2D-TLC experiments it would not be accurate to make such assumptions due to the poor 
separation observed. The same samples were run using solvent system C but due to 
experimental error no data was obtained. 
 
3.7 Standardization of growth protocols 
 
An issue was called to our attention by Dr. Astrid M. van der Sar at the VU University 
Medical Centre in Amsterdam who is performing the zebrafish embryo infection assays of our 
strains. Her group noted some issues with the correlation between OD of grown strains and 
the number of colonies formed when plated. In order to assess this a literature search was 
performed. Gao et al., 2005 state that during log-phase >98% of bacteria are aggregated in 
clusters of >100. The same paper provides protocols specific to M. marinum growth and 
maintenance.  By adopting these techniques we aimed to standardize our methods and provide 
our Dutch collaborators with a set of standard protocols.   
Two practices suggested by the Gao et al, 2005 paper are the low speed centrifugation of 
cultures to pellet clumped cells and the use of a syringe needle to shear cell aggregates.  
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The first experiment was to investigate the effect of centrifugation compared to syringe 
shearing and syringe shearing followed by a centrifugation step. We expected that 
centrifugation would result in a large decrease in colony formation compared to un-treated 
cultures, whilst passing culture through a needle would increase number of colony forming 
units. Centrifugation after syringe-pass should then have little effect on number of colony 








OD600 values of the cells taken after each amendment followed the expected trend (Fig 3.16.). 
Centrifuged cultures show a large decrease in OD600. Passing culture through a syringe 
showed a small increase in OD600 with a subsequent centrifugation of the same sample 
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Number of colonies formed from each sample after 1 week’s incubation was recorded.  In 
both the wild type and ∆cpn60.1 strains, combined action of syringing and centrifugation 
yielded the greatest CFU. Syringing alone increased CFU in the wild type sample but not in 
the ∆cpn60.1 sample (most likely due to pipetting error due to S+C result).  
For shearing of cell aggregates, cultures were passed through the needle six times (3 x in and 
out). A second experiment was carried out, plating samples of a culture after each subsequent 
needle-pass to study the effect this had on CFU to determine the optimal number of passes. 




Fig. 3.18 The change in OD600 nm observed upon subsequent passes through a syringe-needle 
in both wild type (blue) and ∆cpn60.1 mutant strains of M. marinum. Culture (5 mL) of each 
strain was passed through a syringe needle 5 times. In between each pass, 1 mL of culture was 







Fig. 3.19 The change in CFU observed after subsequent passes through a syringe-needle in 
both wild type (blue) and ∆cpn60.1 mutant strains of M. marinum. Culture (5 mL) of each 
strain was passed through a syringe needle 5 times. In between each pass, 1 mL of culture was 
removed, a serial dilution established and plated on 7H10 agar. CFU was recorded 1 week 
later and the mean value is represented above. 
 
Fig. 3.18 shows the effect of needle passes on OD600 wild type and knockout mutants. There 
was a decrease of OD600 with each subsequent pass through the needle. This is converse to the 
previous evidence that OD600 increases with needle shearing. We also saw a decrease in the 
CFU of both samples with each needle pass (Fig. 3.19). Again, this is opposite to the 
previously observed result that CFU increases when culture is passed through a needle. 
 
To determine the actual effect of passing culture through a needle, cells were observed under 
a microscope and counted using a hemocytometer. Due to the acid-fast nature of M. marinum, 
and the impracticality associated with performing Ziehl-Neelson staining on a vast array of 
samples under time constraints, phase contrast microscopy was used to visualize cells.  
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Cultures of both wild type and ∆cpn60.1 strains of M. marinum were grown to the same 
OD600. A manageable density of cells was determined by creating a serial dilution of cells in 
standard media and observing them on the hemocytometer. Once the dilution was established 
number of cells were counted, with clumps of cells counted as 1 colony-forming unit (cfu). A 
large difference was observed between the cfu of wild type and ∆cpn60.1 M. marinum strains. 
The wild type samples contained around twice as many cfus compared to ∆cpn60.1 (636 
compared to 342). However, this was mostly due to ∆cpn60.1 cells existing in larger clusters 
of cells compared to wild-type. After one pass through the syringe needle the number of cfu 
doubled in both cases (from 636-1183 in wild-type and 342 to 855 for ∆cpn60.1). After the 
second pass the number of cfu increased further, to an uncountable level, with the majority of 
cells existing in clusters of 10 cells or less. 
 
3.8 Assessing biofilm/pellicle formation of M. marinum strains 
 
In our lab extensive previous work had been carried out to assess the biofilm-forming ability 
of ∆GroEL1 mutants and wild type M. smegmatis strains. This was as a result of the 
observation that ∆GroEL1 mutants of M. smegmatis lose the ability to form mature biofilms 
(Ojha et al., 2005). 
 
To assess whether this phenotype was also characteristic of the M. marinum ∆cpn60.1 mutant 
the same assay was performed with this strain. Wild type M. marinum was also assayed as a 
control and the two corresponding strains from M. smegmatis were also assessed.  
 
Assays were performed according to the method outlined in Rao, 2010. However after 1 week 
results were contradictory and non-reliable (Data not shown). An alternative protocol was 
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received from a PhD student working on M. smegmatis biofilm formation (Nandita Keshevan, 
Imperial College London). This new protocol looked specifically at pellicle formation, i.e. 
cell proliferation at the air/water interface. Two-day old cultures of M. marinum were used to 
inoculate 7H9 media (with no Tween-80) and incubated for 1 week. After incubation tubes 
were photographed without moving from the incubator so as to not disturb any pellicle 
formed. All but one sample showed no pellicle formation with cells settled at the bottom of 
each tube (Fig. 19). The one sample in which pellicle had formed, M. marinum wild type 2, 
was anomalous as replicates of the same strain showed no pellicle.  
 
 


















4.1 Loss of cpn60.1 from M. marinum appears to convey resistance to heat-shock 
 
The finding that loss of Cpn60.1 appears to convey resistance upon exposure to high 
temperatures was surprising. The ∆cpn60.1 mutant M. marinum strain was able to survive 
exposure to higher temperatures for a longer time period than wild type (Fig. 3.2; >3 hours at 
45 °C for mutant compared to >3 hours for 45 °C). The loss of cpn60.1 also appeared to 
confer resistance to even higher temperatures (50 °C). GroEL and it’s homologues have long 
been known to a play a role in the heat shock response, even earning them the alternative 
name of heat shock proteins (HSPs). However, in most documented cases, loss of the 
dispensable chaperonin - Cpn60.1 in Mycobacteria tends to have an adverse effect on 
response to heat shock. In M. tuberculosis ∆cpn60.1 mutants were found to be more sensitive 
to 55 °C (Hu et al., 2008). Alternatively, in M. bovis BCG, loss of Cpn60.1 has no effect upon 
cell viability at 42 °C (Wang et al., 2011). Although 42 °C is not as radical a temperature 
deviation as that tested in the M. tuberculosis experiments, it is still above the 37 °C optimal 
physiological growth temperature of M. bovis BCG. No difference in viability was observed 
in M. marinum strains grown at 37 °C, despite an optimal growth temperature of 30 °C. 
Therefore a possible role for Cpn60.1 in M. bovis BCG might be elucidated if ∆cpn60.1 
mutant strains were exposed to higher temps.  
 
The evidence gathered in this study appears to suggest that unlike the findings of other studies 
into Mycobacterial Cpn60.1-knockouts, in M. marinum, Cpn60.1 loss actually appears to be 
advantageous, increasing viability at higher temperatures.  It is unclear as to whether this is 
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due to the function of an alternative protein compensating for Cpn60.1 loss or an example of 
another moonlighting function of Cpn60.1 specific to M. marinum.  
 
In order to confirm this result is definitely a consequence of CPn60.1 knockout, the heat-
killing experiments could be repeated with a complemented strain of M. marinum ∆cpn60.1. 
Alternatively, the genome of both wild type 1 and 2, ∆cpn60.1 1#1 and 2#1 strains have been 
sequenced, so genome-wide alignments could be used to identify any single nucleotide 
polymorphisms (SNPs), or potentially larger regions of sequence difference could be 
identified.  
 
4.2 Induction of the M. marinum cpn genes is increased in response to heat-shock 
 
As a result of the heat-killing experiment findings the expression of the cpn genes was 
investigated using qRT-PCR. Previous studies have shown that the expression of the 
chaperonin genes is responsive to different stresses, especially as a result of heat-shock 
(Stewart et al., 2002; Rao & Lund, 2010). It is also worth noting that the expression of 
individual cpn genes is differential under stress conditions, i.e. not equal, with certain genes 
more highly expressed than others, indicative of a divergence of function.  
 
The increased temperature-resistance of the ∆cpn60.1 strain of M. marinum was hypothesized 
to be as a result of Cpn60.2 compensation for Cpn60.1 loss. Both wild type and mutant M. 
marinum strains were subjected to heat shock at 45 (°C). In wild type samples all cpn genes 
were shown to have an increase in expression upon heat shock, in agreement with the findings 
of Stewart et al., (2002), and Rao and Lund, (2010) in M. tuberculosis and M. smegmatis, 
respectively. Highest levels of expression were observed at 10 minutes post temperature 
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increase. Smaller time-points (5, 10, 15, 30 minutes) were used by Rao & Lund (2010) when 
investigating the change in M. smegmatis cpn expression during heat shock, but the overall 
pattern of expression (initial large increase of fold induction followed by slow decline) was 
the same as observed in M. marinum (Fig. 3.10). Results obtained for expression in ∆cpn60.1 
strains were conflicting, mostly due to issues surrounding RNA quality. A spectrophotometric 
measurement had been the only method of detecting RNA yield from purification, however 
this is by no means representative of the quality of purified RNA.  Use of technology such as 
the Bioanalyser 2100 (Agilent technologies) could have provided this information that would 
have informed quantity of RNA used for cDNA synthesis. If RNA quality were found to not 
be the issue then poor cDNA yields would mostly likely be as a result of poor amplification of 
DNA by the random hexamer primers. Efforts were made to optimize this cDNA synthesis 
protocol by increasing the time of the extension step and by the use of betaine or DMSO but 
all were found to have no effect. An alternative approach could involve the use of gene-
specific primers to create cDNA of the genes of interest rather than of the whole 
transcriptome of the cell. Assuming the rate of amplification of each gene was identical 
between primer pairs used then qRT-PCR could still be used to detect relative expression of 
each of the genes. 
 
For ∆cpn60.1 M. marinum cDNA samples, expression of Cpn60.1 was detected, despite the 
absence of the cpn60.1 gene. Expression of cpn60.2 was shown to significantly increase in 
heat-shocked ∆cpn60.1 samples (Fig. 3.12). Replicate runs of the same experiment (Fig 3.13) 
on new cDNA samples showed the same trend of an increase cpn60.2 expression, although 
not to such a high degree as shown in Fig. 3.12. The result from run 1 of 2 was most likely 
anomalous due to the low concentration of reaction template obtained from the first cDNA 
synthesis attempt. However, it does appear that cpn60.2 expression is increased in the 
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knockout strain to compensate for cpn60.1 loss, showing a ~9-fold change (Fig. 3.13) in 
induction compared to ~2-fold change observed in wild-type samples (Fig. 3.11) 
 
To determine the larger effects cpn60.1 loss has on the overall transcriptome, a larger scale, 
genome-wide transcriptome analysis could be used. Microarrays and RNA-Seq are nboth 
widely used technologies that allow the comparison between the relative levels of 
transcription between many genes under different physiological conditions. These 
technologies could be used to contrast the transcriptomes of both wild type and ∆cpn60.1 
strains grown under standard and heat-shock conditions. 
 
4.3 Further evidence that Cpn60.1 is most likely required for proper establishment of the 
Mycobacterial cell wall  
 
Cpn60.1 is important for cell wall synthesis. In M. smegmatis the synthesis of mycolates 
during the formation of biofilms requires Cpn60.1 (Ohja et al., 2005). In M. bovis BCG, 
∆cpn60.1 mutants fail to synthesise the phthiocerol dimycocerosate class of lipids, important 
for virulence of both M. bovis BCG (Beatty et al., 2002) and M. tuberculosis (Asterie-
Dequeker et al., 2009). These findings led to the investigation of the lipid profiles of our M. 
marinum strains. Two key differences were observed in the lipids from the ∆cpn60.1 strain 
separated by solvent system B and C. The position of these altered lipids can be compared to 
Fig 4.1, which shows the position and identity of M. tuberculosis lipids separated using the 
same method (Bhatt et al., 2007a). This suggests that the overexpressed lipids observed in the 
∆cpn60.1 strain of M. marinum are either free fatty acids or free mycolic acids. Efforts to 
restore phenotype by complementation were unsuccessful mostly due to time constraints of 
the project. Although various complemented mutant strains were achieved only one run of 
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2D-TLC could be performed and the results were likely unreliable. Mass spectrometry or 
high-performance liquid chromatography could be used to validate the identity of altered 
lipid.  
Altered expression of mycolic acids has been shown to have significant effects on 
morphology and immune response to M. tuberculosis. Deletion of one of the genes 
responsible for mycolic acid synthesis, kasB, in M. tuberculosis drastically altered colony 
morphology of cells (Bhatt et al., 2007a). ∆cpn60.1 M. marinum strains displayed distinct 
phenotypic characteristics different to those observed in wild-type strains. Therefore, the 
change in cell wall composition observed in ∆cpn60.1 M. marinum could be as a result of the 
altered mycolic acid expression.  
 
 
Fig. 4.1 The position and identity of specific apolar lipids of M. tuberculosis separated using 







Wild-type cells have the propensity to exist in clusters (up to 98% of cells during log-phase; 
Gao & Manoranja, 2005). Microscopy was used to observe the cell-clumping tendency of 
∆cpn60.1 cells and this was found to be much higher than in wild type, with clusters 
comprised of twice the number of cells forming in ∆cpn60.1 cultures. This increased 
clumping was also visible to the naked eye and was associated with increased adherence of 
mutant cells to glassware used in culturing. 
 
Methods for overcoming clusters of cells are described in Gao & Manoranjan, 2005. Use of a 
syringe needle in combination with a low-speed centrifugation step to pellet any larger, 
heavier clusters was found to be most effective. Three passes through a 23G syringe needle 
was sufficient to shear the majority of cell clusters in both wild type and ∆cpn60.1 strains of 
M. marinum.  
 
The findings of this study appear to indicate that the role of Cpn60.1 in M. marinum is typical 
of the moonlighting functions associated with this dispensable chaperonin. Loss of cpn60.1 
appears to convey a resistance to higher temperatures that are lethal to wild type cells. This is 
either due to a suicide-promoting role of Cpn60.1 under heat shock or more likely due to an 
increased expression of Cpn60.2 to compensate for the loss of Cpn60.1 protein. The correct 
establishment of the M. marinum cell wall also appears to require the action of Cpn60.1, 
however the mechanism remains unknown. Overall, cpn60.1 shows promise as a potential 
target for the development of anti-TB drugs and M. marinum remains one of the most 
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6. SUPPLEMENTARY INFORMATION 
 
6.1 Further information regarding qRT-PCR primers 
 
Name Length (bp) Tm (°C) GC content (%) 
Mm_cpn10_F 21 63.95 52.38 
Mm_cpn10_R 20 64.09 60.00 
Mm_cpn60_1_F 20 65.22 60.00 
Mm_cpn60_1_R 22 64.74 54.55 
Mm_cpn60_2_F 21 64.87 57.14 
Mm_cpn60_2_R 21 64.57 57.14 
Mm_gapdh_F 20 61.88 60.00 
Mm_gapdh_R 20 61.89 50.00 
 
Supplementary Table 1. Key properties of qRT-PCR primers. Tm refers to the melting 











6.2 Additional TLC data 
 
6.2.1 M. marinum polar lipids separated using system E 
 
 
Supplementary Fig. 1 2D-TLC of polar lipids purified from M. marinum wild-type and 


















6.2.2 2D-TLC of Polar lipids from M. smegmatis wild type and ∆cpn60.1 strains  
 
Supplementary Figure 2. 2D-TLC of Polar lipids from M. smegmatis wild type (left) and 











6.2.2 2D-TLC of Apolar lipids from M. smegmatis wild type and ∆cpn60.1 strains  
 
 
Supplementary Figure 3. 2D-TLC of Apolar lipids from M. smegmatis wild type (left) and 
∆cpn60.1 (right) strains using solvent systems A-D (referred to by letters on left hand side of 
diagram). 
 
Wild type ∆cpn60.1 
A 
B 
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